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Abstract 
Lipid droplets (LD) are intracellular organelles controlling neutral lipid metabolism 
and storage. One of the recently discovered functions of LDs is the essential role they play 
in aging process. Alterations in membrane lipid composition are one of the major changes 
that are shown to take place in many of the aging models. An increase in cholesterol to 
phospholipid ratio was reported in rat models of aging. A reduction in the level of 
polyunsaturated fatty acyl is the next important age related variable observed in these aging 
systems. However, there is no systematic report characterizing the lipid composition of 
lipid droplets in aging models including Caenorhabditis elegans and mouse liver tissue.  
In this thesis, ultra-high performance liquid chromatography coupled to mass 
spectrometry techniques were used to characterize the composition of lipid droplets. The 
performances of two high resolution mass spectrometers were compared with regards to 
detection and identification of small hydrophobic molecules. Different software packages 
and bioinformatics tools were compared to discover possible variation of the extracted 
information. The selected mass spectrometry platform and optimized data analysis 
workflow were used to study lipid droplets and identify candidate biomarkers of aging. 
Preliminary identifications made here could potentially be used as biomarkers in 
aging diseases and could ultimately lead to treatments for age-related disorders.   
 iv 
 
Table of Contents 
 
List of Tables .................................................................................................................... vii 
List of Figures .................................................................................................................. viii 
List of Abbreviations ......................................................................................................... ix 
Chapter 1: Introduction ....................................................................................................... 1 
Chapter 2: Background ....................................................................................................... 6 
2.1. Metabolomics ............................................................................................................... 7 
2.1.1. Lipidomics ............................................................................................................. 7 
2.1.2. Cellular Functions of Lipids .................................................................................. 9 
2.2. Lipid Droplets and Their Role in Disease.................................................................. 11 
2.3. Methods to Analyze Lipids ........................................................................................ 13 
2.3.1. Sample Preparation.............................................................................................. 13 
2.3.2. Non Mass Spectrometry Based Approaches ....................................................... 15 
2.3.3. Mass Spectrometry in Lipidomic Research......................................................... 18 
2.4. Data Processing for Mass Spectrometry Based Lipidomics ...................................... 22 
Chapter 3: Comparison of High Resolution Quadrupole-Time-of-Flight and LTQ-
Orbitrap Mass Spectrometers for Lipidomic Analyses ..................................................... 27 
3.1. Introduction ................................................................................................................ 29 
3.2. Materials and Methods ............................................................................................... 32 
3.2.1. Reagents .............................................................................................................. 32 
3.2.2. Sample Preparation and Extraction ..................................................................... 33 
3.2.3. LC/MS Conditions .............................................................................................. 34 
3.2.4. Data Treatment .................................................................................................... 36 
3.3. Results ........................................................................................................................ 39 
3.3.1. Reproducibility .................................................................................................... 41 
3.3.2. Mass Accuracy .................................................................................................... 43 
3.3.3. Mass Resolution .................................................................................................. 47 
3.3.4 Signal to Noise Ratio............................................................................................ 49 
 v 
 
3.3.5. Data Analysis ...................................................................................................... 54 
3.4. Discussion .................................................................................................................. 57 
3.5. Conclusions ................................................................................................................ 61 
Chapter 4: Comparative Lipidomic Analysis of lipid droplets from C. elegans at Different 
Ages .................................................................................................................................. 63 
4.2. Materials and Methods ............................................................................................... 67 
4.2.1. Reagents .............................................................................................................. 67 
4.2.2. Lipid Droplet (LD) Isolation ............................................................................... 68 
4.2.3. Metabolite (Lipid) Extraction .............................................................................. 69 
4.2.4. Lipid Quantification ............................................................................................ 70 
4.2.5 LC/MS Conditions ............................................................................................... 70 
4.2.6. Data Processing ................................................................................................... 72 
4.3. Results ........................................................................................................................ 73 
4.3.1. The Composition of Lipid Droplets isolated from C. elegans Differs with Age 74 
4.3.2. Most Significant Lipids Changed in Lipid Droplets with Aging ........................ 85 
4.4. Discussion .................................................................................................................. 87 
4.5. Conclusions ................................................................................................................ 88 
Chapter 5: Lipidomic Analysis of Enriched Lipid Droplets from Young and Geriatric 
Mice Reveals Distinct Signatures of Aging ...................................................................... 89 
5.1. Introduction ................................................................................................................ 90 
5.2. Materials and Methods ............................................................................................... 92 
5.2.1. Reagents .............................................................................................................. 92 
5.2.2 Lipid Droplet Isolation from Mouse Liver Tissue ............................................... 93 
5.2.3. Metabolite (Lipid) Extraction .............................................................................. 93 
5.2.4. Lipid Quantification ............................................................................................ 94 
5.2.5. UPLC/MS Conditions ......................................................................................... 94 
5.2.6. Data Treatment .................................................................................................... 96 
5.3. Results ........................................................................................................................ 97 
5.3.1. Preliminary Identifications from Mouse Liver .................................................... 97 
 vi 
 
5.3.2. Triglycerides Increase in Aged Liver Lipid Droplets........................................ 100 
5.3.3. Phospholipids Decrease in Aged Liver Lipid Droplets ..................................... 103 
5.4. Discussion ................................................................................................................ 104 
5.5. Conclusion ............................................................................................................... 106 
Chapter 6: Conclusions and Future Work ....................................................................... 107 
6.1. Conclusions .............................................................................................................. 108 
6.2. Future Work ............................................................................................................. 111 
6.2.1. Improve and Validate Preliminary Identifications ............................................ 111 
6.2.2. Improving Purification of Subcellular Organelle Enrichment .......................... 113 
6.2.3. Improving Lipid Analysis by Ion Mobility Mass Spectrometry ....................... 114 
Bibliography ................................................................................................................... 117 
Appendices ...................................................................................................................... 130 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vii 
 
List of Tables 
 
Table 2.1. Selected Applications of Lipidomics for Biological and Biomedical Research. .......... 11 
Table 2.2. Examples of scanning modes in lipidomics.  ............................................................ 19 
Table 2.3. Common tools available for LC/MS metabolomics data processing.  ......................... 26 
Table 3.1. Mass accuracies of lipid standards analyzed using the Q-TOF and the LTQ-Orbitrap 
instruments........................................................................................................................... 47 
Table 3.2. Signal to noise values of lipid standards analyzed using the Q-TOF and the LTQ-
Orbitrap.  .............................................................................................................................. 51 
Table 4.1. Summary of hits resulting from the comparative analysis of lipid droplets isolated from 
C. elegans at Day 1 and Day 4 of adulthood. .......................................................................... 75 
Table 4.2. Summary of hits resulting from the comparative analysis of lipid droplets isolated from 
C. elegans at Day 1 and Day 7 of adulthood. .......................................................................... 75 
Table 4.3. Summary of hits resulting from the comparative analysis of lipid droplets isolated from 
C. elegans at Day 7 and Day 7 of adulthood. .......................................................................... 76 
Table A.1. Meta analysis of Day 1 and Day 7 samples.  ......................................................... 133 
Table A.2. Meta analysis of Day 1 and Day 4 samples.  ......................................................... 136 
Table B.1. Summary of significant features of enriched lipid droplets from young and old mouse 
liver observed in positive electrospray ionization. ................................................................. 146 
Table B.2. Summary of significant features of enriched lipid droplets from young and old mouse 
liver observed in negative electrospray ionization. ................................................................ 147 
 
 
 
 
 
 
 
 
 
 
 
 viii 
 
List of Figures 
 
Figure 2.1. Representative structures of lipid classes. ................................................................9 
Figure 2.2. Schematic of lipid droplet composition.................................................................. 13 
Figure 2.3. Number of original papers published over 11 years dedicated to lipidomics and different 
instrumental platforms.  ........................................................................................................ 15 
Figure 2.4. Schematic diagram of the Synapt (A) and Orbitrap (B) instruments. ........................ 22 
Figure 2.5. Summary of metabolomic data processing workflow. ............................................. 23 
Figure 2.6. Workflow for preliminary identification of lipids from LC/MS.  .............................. 25 
Figure 3.1. Representative data for m/z 759.5780. . ................................................................. 40 
Figure 3.2. Reproducibility in technical replicates analyzed on the Q-TOF instrument. .............. 42 
Figure 3.3. Reproducibility in technical replicates analyzed on the LTQ-Orbitrap instrument. . .. 43 
Figure 3.4. Lipid standards used to compare performance of Q-TOF and LTQ-Orbitrap.  .......... 46 
Figure 3.5. Mass resolution comparison. ................................................................................ 49 
Figure 3.6. Relative signal to noise values. . ........................................................................... 53 
Figure 3.7. Number of potential assignments to molecular identities using different software 
platforms. . ........................................................................................................................... 56  
Figure 4.1. Preliminary identification of m/z 942.8615 in lipid droplet enriched fractions of Day 1 
and Day 4 samples. ……………………………………...……………………………………….  77  
Figure 4.2. Preliminary identification of m/z 922.7050 in lipid droplet enriched fractions of Day 1 
and Day 7 samples. . ............................................................................................................. 78 
Figure 4.3. Preliminary identification of m/z 596.5379 in lipid droplet enriched fractions of Day 4 
and Day 7 samples. . ............................................................................................................. 79 
Figure 4.4. Comparative visualization of Day 1 versus Day 4 data.  ......................................... 81 
Figure 4.5. Comparative visualization of Day 1 versus Day 7 data. .......................................... 82 
Figure 4.6. Comparative visualization of Day 4 versus Day 7 data. .......................................... 83 
Figure 4.7. Heat map of relative abundance of features commonly detected in D1, D4, and D7 
samples.  ............................................................................................................................... 85 
Figure 5.1. Mass spectrometry results of enriched lipid droplet fractions in young and old mouse 
liver samples in positive ESI.................................................................................................. 99 
Figure 5.2. Mass spectrometry results of enriched lipid droplet fractions in young and old mouse 
liver samples in negative ESI. .............................................................................................. 100 
Figure 5.3. Preliminary Identification of m/z 929.7541. ......................................................... 102 
Figure 6.1. Diagram of an immunoisolation experiment using magnetic beads.  ....................... 114 
 
 
  
 ix 
 
List of Abbreviations 
 
AGC: Automatic gain control 
APCI: Atmospheric pressure chemical-ionization  
APPI: Atmospheric pressure photo-ionization  
BHT: Butylated hydroxytoluene  
C.elegans: Caenorhabditis elegans 
CE: Capillary electrophoresis  
CL: Cardiolipin 
CS: ChemSpider 
CV: Coefficient of variation  
CVD: Cardiovascular disease 
D1: Day 1 
D4: Day 4 
D7: Day 7 
DI: Deionized water 
DMEM: Dulbecco’s Modified Eagle Medium 
EDTA: Ethylenediaminetetraacetic acid 
ESI: Electrospray ionization 
FA: Fatty Acid 
 x 
 
FAB: Fast atom bombardment  
FTICR: Fourier transform ion cyclotron resonance 
GC: Gas chromatography 
h: Hour 
HDMS: High definition mass spectrometry 
HEPES: 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
IM: Ion mobility  
IM/MS: Ion mobility combined with mass spectrometry 
LC: Liquid chromatography  
LD: Lipid droplets  
MALDI: Matrix assisted laser desorption ionization  
min: Minute 
MRM: Multiple reaction monitoring  
MS: Mass spectrometry  
NL: Neutral loss scanning 
NMR: Nuclear magnetic resonance spectroscopy 
Oa- TOF: Orthogonal acceleration time of flight 
PA: Phosphatidic acid 
PBS: Phosphate buffered saline 
PC: Phosphatidylcholine 
 xi 
 
PCA: Principle component analysis 
PE: Phosphatidylethanolamine 
PG: phosphatidylglycerol 
PI: Phosphoinositide 
PNF: Post nuclear fraction 
ppm: Parts per million  
PREC: Precursor ion scanning 
PS: Phosphatidylserine 
Q-TOF: Quadrupole time of flight 
S/N: Signal to noise 
s: Second 
SPM: Sphingomyelin 
SPV: Sulfo-phospho-vanillin  
Std Dev: Standard deviation 
TAG: Triacylglyceride 
TIC: Total ion chromatogram 
TLC: Thin-layer chromatography (TLC) 
TOF: Time of flight 
UPLC: Ultra performance liquid chromatography 
UPLC/MS: Ultra performance liquid chromatography coupled to mass spectrometry 
 xii 
 
UV: Ultraviolet   
XIC: Extracted ion chromatograms 
 1 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1: Introduction  
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With a progressively growing elderly population, aging-associated pathologies 
such as heart disease, cancer, Alzheimer’s, and diabetes are imposing a burden on global 
health.1,2 It is estimated that the number of people 65 years of age and older is growing 
significantly from 524 million in 2010 to 1.5 billion in 2050.3 In less developed countries 
the number of older people is expected to increase more than 250% between 2010 and 
2050. Therefore, the study of aging and age-related diseases is vital to accompany the aging 
population with better health and wellbeing. The progression of aging is well known to 
result in dramatically altering lipid metabolism including lipid accumulation in skeletal 
muscle of aging patients.4,5  
Lipid droplets (LD), the energy-reserve organelles, are dynamic organelles 
controlling neutral lipid metabolism and storage and participate in many critical cellular 
pathways.6-9 One of the recently discovered functions of LDs is the essential role they play 
in longevity regulation.10 Although the role and biogenesis of lipid droplets are relatively 
well studied, little is known about their composition and structure in aging.11,12 Further 
characterization of lipid droplets is necessary to understand how the dynamics of this 
organelle is affected during chronological aging process which could ultimately lead to 
treatments for age-related disorders and diseases.13 The elucidation of the distribution of 
lipids in subcellular organelles is a major challenge. Lack of methodologies and proper 
tools to analyze and process the complex data generated by untargeted lipid analysis makes 
it further complicated.14 To address this issue, several lipidomics workflows have been 
developed to make reliable identifications of individual lipid species.  
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The goal of this thesis was to investigate the composition of lipid droplets during 
aging. Mass spectrometry methods and bioinformatics tool were utilized to gain insights 
of the composition of enriched lipid droplets from the worm Caenorhabditis elegans (C. 
elegans) and mouse liver tissues. A non-targeted liquid chromatography coupled to mass 
spectrometry (LC/MS) method and bioinformatics were applied to make preliminary 
identifications of lipids with altered abundance in lipid droplets during aging.  
Chapter 2 covers the background of this thesis to expand upon the key points related 
to biochemistry of lipids and their major tasks in energy storage, structural functions, and 
cellular signaling. This chapter introduces lipid droplets as the subcellular organelles that 
store neutral lipids, and their importance in maintaining the health of an organism. Several 
analytical techniques used widely in lipidomic studies of biological matrices are discussed. 
This chapter further summarizes the computational tools for successful functional 
interpretation of lipidomic experiments.  
Chapter 3 describes a comparison of two high resolution mass spectrometry 
platforms for lipidomic analyses. The level of diversity and high degree of molecular 
heterogeneity of lipids generates a need in developing advanced analytical methodologies . 
The goal of this study was to evaluate the performances of the two mass analyzers in terms 
of number of detected features, ability to utilize enhanced resolution to better resolve 
analytes in complex matrices, metabolite identification, and detection of very low abundant 
compounds. This chapter describes several bioinformatic tools and software packages and 
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compares the main data processing steps used in metabolomics research. Synapt G2 Q-
TOF mass spectrometer and XCMS software were chosen for further studies.  
 Chapter 4 covers the bioanalytical strategies used to identify small molecules and 
lipids that significantly change in abundance between different C. elegans age populations. 
This chapter describes C. elegans as a model organism that has contributed significantly to 
the understanding of the biology of aging of multicellular organisms, including humans. 
The goal of this chapter was to investigate and compare the age related changes to the 
composition of lipid droplets purified from Day 1, Day 4, and Day 7 worms utilizing 
LC/MS. Our analysis identified unique lipid profiles specific to the age of the worm. We 
observed that lipid droplets have increased triglyceride content and decreased phospholipid 
content with age.  
 Chapter 5 describes LC/MS analysis of lipids in lipid droplet fractions of young 
and geriatric mice liver tissue. The goal of this chapter was to characterize age specific 
distributions of lipids. Preliminary identifications show that enriched lipid droplet fractions 
have characteristic lipidomic profiles specific to their age including increased triglyceride 
and decreased phosphatidylcholine and phosphatidylethanolamine content with age. 
Preliminary identifications made here could be further validated and investigated for their 
specific role in aging.  
 Chapter 6 covers the conclusions and future work. We have characterized the 
lipidome of lipid droplets in two different model organisms under different age conditions. 
These preliminary identifications are valuable in understanding the composition of lipid 
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droplets and changes in their compositions in aging. This chapter also describes future 
improvements to the analytical techniques, including sample preparation, LC/MS analysis, 
validation of the preliminary identifications, and bioinformatics of lipidomic data.  
Overall, the work described in this thesis contributes to our fundamental 
understanding of lipid droplets and how their lipidomic profile changes in aging. The 
findings in this thesis add significantly to the field of lipidomic analysis and may result in 
new studies to determine the role of aging in lipid droplet biology. 
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Chapter 2: Background  
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2.1. Metabolomics 
Metabolomics employs analytical instrumentation to comprehensively identify and 
analyze hundreds of small molecules (metabolites) in a given biological sample (biofluid, 
tissue, cells, etc.).15 Metabolomics play a major role in early detection and diagnosis of 
variety of diseases that are known to alter cellular metabolism.16 Recent advances in 
analytical instrumentation including mass spectrometry and statistical tools have provided 
metabolomics the ability to probe much further into disease biomarker discovery.17 The 
search for metabolites as biomarkers has been particularly common in the area of 
neurodegenerative disease. Metabolomic studies of aging have sought potential biomarkers 
of age-related diseases.18 Comparing quantifications of individual metabolites between 
diseased and control individuals allows researchers to determine if specific molecules are 
significantly different between the two groups. Modern metabolomics depends almost 
entirely on analysis by mass spectrometry and chromatography techniques which have 
greatly promoted the field.19 There are two main subtypes: targeted metabolomics, which 
measures a selected set of metabolites20 and untargeted metabolomics, which assesses 
metabolites in an unbiased manner.21,22 In both targeted and untargeted metabolomics, 
quantification is performed by comparing signal intensities across different sample groups. 
2.1.1. Lipidomics 
 
Lipids are ubiquitous group of compounds exhibiting enormous structural diversity 
and are grouped under the following eight categories: Fatty acids, Glycerolipids, 
Glycerophospholipids, Sphingolipids, Sterols, Prenols, Saccharolipids, and Polyketides. 23 
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Representative structures of lipid classes are summarized in Figure 2.1. Each category 
contains distinct classes, subclasses, subgroups, and subsets of lipid molecules with 
different physiochemical properties.24 Polar lipids including glycerophospholipids, 
sphingolipids, and sterol lipids are classified based upon their headgroup moieties and 
interact with membrane proteins via hydrogen bonding. Neutral or non-polar lipids 
including sterol esters and glycerolipids participate in non-covalent interactions through 
their hydrocarbon chains with other lipids and hydrophobic regions of proteins.25 These 
interactions have important consequences for the mechanisms of lipid functions. 
The large number of categories and the extremely complex structures of lipids lead 
to a formidable challenge to comprehensively analyze lipids in biological matrices. The 
large-scale analysis of lipids in cells and tissues was made possible by a newly emerged 
discipline known as lipidomics.26,27 Lipidomics studies lipids on a large scale utilizing 
analytical chemistry principles and technological tools, particularly mass spectrometry.   
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Figure 2.1. Representative structures of lipid classes. (A) Fatty Acyls, (B) Glycerolipids, (C) 
Glycerophospholipids, (D) Sphingolipids, (E) Prenol lipids, (F) Sterol lipids, (G) Saccharolipids, (H) 
Polyketides.  
2.1.2. Cellular Functions of Lipids 
 
Lipids play fundamental roles in maintaining cell membranes, participating in cell 
signaling pathways, serving as energy storage, and regulating cellular function and 
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disease.28 Dysfunction in the lipid homeostasis has shown to be a risk factor for cancer, 
obesity, aging, and the many types of neurodegenerative disorders, including Alzheimer's 
disease, Huntington's disease, and Parkinson's disease.29,30 Recent lipidomic studies have 
identified characteristic lipid signatures that have potential as diagnostic tools.31 A 
summary of selected applications of lipidomics in biological and biomedical research is 
provided in Table 2.1.  
The work described in this thesis investigates the changes to the lipid droplet 
lipidomic profiles with regards to aging. Aging is driven by lifelong accumulation of 
unrepaired cellular and molecular damage and is generally recognized as a process that 
results in the progressive decline of an organism over time.2 It is predicted that by 2050 
almost 25% of the world's population will be over 60 years of age.3 Much data have been 
gathered on age dependent alterations in membrane lipid composition of different organs 
and tissues of mammals. One of the major compositional changes that is shown to take 
place in many of the aging systems is an increase in cholesterol to phospholipid ratio.32 A 
reduction in the level of polyunsaturated fatty acyl is the next important age related variable 
observed in these systems.33 Another commonly cited change is an increase in the ratio of 
sphingomyelin (SPM) to phosphatidylchofine (PC).34-36 Altered lipid compositions seem 
to affect many membrane associated activities. Among these are the activity of various 
enzymes, signal transduction, the interaction of the receptors with the membrane bilayer, 
membrane permeability and potential, and transport of small molecules. So, it is important 
to gain a mechanistic understanding of the impact of aging on the dynamics of lipid 
metabolism in the biological systems. 
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Application Type Technique Source of lipids Findings and implications 
Metabolic 
syndrome 
Cardiovascular 
disease (CVD) 
LC-based; 
shotgun; 
liquid 
extraction 
surface 
analysis; 
GC-MS 
Plasma and 
tissue (e.g., 
plaque) 
New insights into the association of molecular 
lipids with CVD; unraveling the lipid 
heterogeneity within atherosclerotic lesions; 
revealing biomarkers of atherosclerosis; 
understanding obesity risk factor of CVD; 
identifying lipidomic and metabolomics risk 
markers of vascular diseases 
 
 Diabetes and 
obesity 
LC-
MS/MS; 
flow 
injection 
MS; 
shotgun; 
GC 
Plasma Positive association of plasma lipids with obesity; 
association of plasma lipidome with type 2 
diabetes and similar association present in 
prediabetes; exploring the role of metabolomics 
analysis in diabetes research relating to the 
development of diabetes in children and changes 
in obese children with weight loss 
 
Neurologic
al disorders 
Alzheimer's 
disease; 
Huntington 
disease; multiple 
sclerosis 
LC-MS and 
MS/MS; 
shotgun 
CSF; brain 
tissue; plasma; 
serum 
Alterations in phospholipids; increased levels of 
diglycerides and others; reduced cholesteryl 
esters; changed lipid mediators; platelet activating 
factors as potential biomarkers in inflammation 
and neurodegeneration 
     
Cancer Breast; prostate; 
lung; ovary; 
esophagus; 
kidney; skin 
LC-MS and 
MS/MS; 
shotgun; 
MALDI 
imaging; 
DESI-MS 
imaging 
Plasma; tumor 
tissue; human 
and mouse 
squamous cell 
carcinoma 
A panel of lipids as biomarkers; accumulation of 
cholesteryl esters; acyl chain elongation; high 
lysoPC and lower PC and TG; changed 
phospholipids; increased content if species 
containing PUFA; the role of cycloxyenase-2 in 
tumorigenesis 
 
Table 2.1. Selected Applications of Lipidomics for Biological and Biomedical Research.37 
 
2.2. Lipid Droplets and Their Role in Disease 
 
Lipid droplets (LDs) are the major cellular organelles to store neutral lipids, such 
as triglycerides and sterol esters, in their core (Figure 2.2).38 The surrounding phospholipid 
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monolayer is composed of over a hundred of different phospholipid molecular species 
protecting the neutral lipids from the hydrophilic environment of the cell. The variety of 
the different phospholipids in this monolayer fulfills important tasks in regulating the 
structure and function of this cellular organelle.39 LDs function as building blocks for 
membrane synthesis and energy reservoirs that can be released when food is scarce. They 
also function in multiple other cellular processes, such as protein storage, autophagy, lipid 
transport and metabolism.40,41 
Alterations in LD lipid profiles are associated with many diseases including 
obesity, cancer, liver disease, and cardiovascular disease.42 Recently there has been 
remarkable advancement in understanding of LD biology and the role they play in health 
and disease. These LDs related studies usually only focus on analyzing the composition or 
changes of the LDs associated proteins which are embedded in the phospholipid 
monolayer.43 However, the association between the changes of the LDs lipidome and  
regulation of cellular signal pathways is usually neglected. The lack of data about lipidomic 
composition of LDs hampers a detailed understanding of how they response to  changes 
during different biological conditions. To address this issue, the work described in Chapter 
3 and Chapter 4 investigates the age related differences in lipid composition of lipid 
droplets in two different model organisms. 
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Figure 2.2. Schematic of lipid droplet composition.44,45 
2.3. Methods to Analyze Lipids 
 
2.3.1. Sample Preparation 
 
Characterization and identification of lipids in biological membranes is highly 
dependent upon the preparation of high purity, morphologically distinct membranes or 
subcellular fractions.23 Sample preparation should be quick and performed at controlled 
temperatures in the presence of antioxidants and inhibitors of hydrolytic enzymes and 
proteases to prevent lipid degradation and oxidation. To achieve optimal isolation extra 
care should be taken for the following steps: homogenization, membrane fractionation, and 
lipid extraction.46   
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Homogenization steps can dramatically impact the yield and purity of the specific 
organelles and affect the chemical integrity of extracted lipids.47 Liquid homogenization 
was used in the work described in this thesis utilizing a Dounce homogenizer. The Dounce 
Homogenizer, also known as a tissue grinder, works by manually disrupting cells. This 
type of homogenizer is ideal for preparation of cell lysates or other tissues, and allows for 
maximum friction and cell disruption.  
A variety of fractionation methods has been employed based on density gradient 
centrifugation, affinity chromatography, and immunoaffinity purification using antibodies 
specific for markers enriched in these fractions.48,49 Density gradient centrifugation was 
used to isolate lipid droplets in this work. With a density less than water (specific gravity 
0.92 g/cm3), lipid droplets float easily in aqueous solutions such as sucrose buffer. 
The effectiveness of lipid extraction procedures highly depends on the chemical 
nature of the lipid components. Typically, a phase separation is created between immiscible 
solvents, with the lipids partitioning into the hydrophobic phase. Here, several methods 
were tested and a chloroform:methanol (1:2) based extraction was chosen to extract total 
lipids from lipid droplet samples. This method by Bligh and Dyer is regarded as the most 
reliable method for complete recovery of total lipids. A description of lipid extraction 
protocols and a comprehensive comparison of solvents used for lipid extraction are 
outlined on the Cyberlipid website (www.cyberlipid.org).23  
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2.3.2. Non Mass Spectrometry Based Approaches 
 
The separation techniques that have been traditionally carried out for lipid analysis 
include thin-layer chromatography (TLC), gas chromatography (GC), capillary 
electrophoresis (CE), high performance liquid chromatography (HPLC), nuclear magnetic 
resonance (NMR) spectroscopy, and mass spectrometry (MS).50 (Figure 2.3) 
 
Figure 2.3. Number of original papers published over 11 years dedicated to lipidomics and different 
instrumental platforms.51  
 
TLC is a simple chromatographic technique that allows the separation in a single 
run of a mixture of lipids with widely different polarities.52,53 This method is easy to carry 
out and does not require complicated instrumentation and allows rapid screening of lipid 
extracts. Detection in TLC is generally based on the UV or visible absorption of the solutes 
or on the use of various detection reagents such as iodine vapor and class specific 
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dyes/radioactivity.54 However, TLC based experiments are time consuming and lack 
resolution power, reproducibility, and specificity.  
The advent of gas chromatography with MS based detection techniques has led to 
the analysis and identification of individual fatty acid molecular species, TAGs and 
sterols.55 GC analysis is conducted at high temperatures that may result in lipid 
isomerization or decomposition. Multiple derivatization steps needed to improve volatility 
can be an issue for the analysis of low abundance lipid species. These steps are time 
consuming, and a major drawback of these methods is the large amount of starting material 
required for the derivatization.56 
Nuclear magnetic resonance (NMR) has also been commonly used for the structural 
analyses and quantification of lipid species. Proton NMR, 31P-NMR, and 13C-NMR have 
been utilized to analyze lipid profiles of human erythrocytes57 and the phospholipid 
composition of tissues and body fluids.58 Two dimensional NMR was recently reported for 
the untargeted analysis of mycobacteria lipid compositions.59 NMR spectra are dominated 
by very abundant lipids such as phosphocholine and cholesterol.54 NMR suffers from low 
sensitivity which compromises the ability of this technique to resolve low abundance lipids. 
Capillary Electrophoresis (CE) is a high-resolution technique for the separation of a 
wide range of lipids.50 The most common capillary electrophoresis modes used in the 
context of lipid analysis include capillary zone electrophoresis, micellar electrokinetic 
chromatography, and microchip capillary electrophoresis. Lipid aggregation especially at 
concentrations above their critical micellar point is among the difficulties encountered with 
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the use of capillary electrophoresis for lipid separation. The other disadvantage of CE in 
lipid determination is the inability to resolve extremely hydrophobic lipids that are difficult 
to dissolve in aqueous electrolyte buffers. In addition, many solvents, buffer additives, and 
other analytes absorb in the region of 190–220 nm which pose a major challenge for the 
determination and quantitation of lipids by ultraviolet (UV) detection.23  
High performance liquid chromatography (HPLC) is an easily automated method 
for separation and quantification of lipids.54,60 HPLC has been applied for determining the 
lipid profiles of lipid mixtures using ultraviolet, fluorescence, flame ionization, refractive 
index or mass spectrometric detection methods. LC has become increasingly popular for 
obtaining maximum possible coverage since the majority of the metabolites in biological 
samples are non-volatile. Another advantage of LC over GC is due to the large diversity of 
separation mechanisms including normal phase (silica), reverse phase (C18, C8, C4, and 
phenyl), and hydrophilic interaction chromatography (HILIC).61 Normal-phase HPLC 
generally separates phospholipids based on the polarity of their head groups, whereas the 
mechanism of action in reversed-phase chromatography is based on the lipophilicity of 
lipids, which is governed by the carbon chain length and the number of double bonds. 
HILIC is considered a variant of normal-phase chromatography and could be used to 
separate lipids according to their polarity.62,63 Recently, decreased particle sizes of columns 
have allowed for improved resolution, sensitivity, decreased run time, and provides much 
higher separation power and peak capacity compared to conventional HPLC columns. This 
has been coined as ultra-performance liquid chromatography (UPLC).64 UPLC has 
increased pressure and decreased particle size packed in the column to improve resolution 
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of adjacent chromatographic peaks allowing improved detection compared to conventional 
HPLC. Using UPLC leads either to better separation of narrower chromatographic peaks 
or to faster analysis without the loss of resolution.  
2.3.3. Mass Spectrometry in Lipidomic Research 
 
New mass spectrometry-based tools are advancing the number and types of lipids 
that can be identified and quantified.27,65,66 A mass spectrometer has three essential 
components: (i) an ion source that converts the sample molecules into charged ions in the 
gas phase; (ii) a mass analyzer employs electric and/or magnetic fields to sort ions 
according to their m/z values; and (iii) a detector that measures the signal of each m/z-
resolved ion. 
The ionization source in modern mass spectrometers include electrospray (ESI), 
atmospheric pressure chemical-ionization (APCI), atmospheric pressure photo-ionization 
(APPI), and matrix assisted laser desorption ionization (MALDI). Choosing a particular 
mass spectrometry ionization technique strongly depends on the lipid class to be 
analyzed.67,68 It is generally accepted that ESI is best suited for studying complex biological 
samples as minimal daughter ions are produced (soft technique) which allows compounds 
to be studied in the mass spectrometer. By employing both positive and negative ESI 
modes, as well as adjusting the pH of the lipid extract, it is possible to preferentially ionize 
various lipid classes under different experimental conditions (Table 2.2). APCI is usually 
used to analyze relatively nonpolar molecules with lower molecular weight like Sterols. 
APPI provides the highest S/N ratio in analyzing lipid molecular species separated by 
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normal-phase liquid chromatography.62 MALDI is another soft ionization technique 
commonly used for lipid analysis.69 Unlike ESI, MALDI can ionize the analyte directly 
from the solid phase. MALDI is mostly used in imaging mass spectrometry for 
investigating the distribution of lipids through the direct analysis of thin solid phase tissue 
sections.70-72  
Subclass Polarity Mass-to-charge ratio (m/z) 
Glycerophosphocholine Positive 184  
Negative 168 
Glycerophosphoethanolamine Positive 141 
 
Negative 195 
Glycerophosphoserine Positive 185 
 
Negative 87 
Glycerophosphoinositol Positive 277 
 
Negative 241 
Glycerophosphoglycerol Positive 189 
Glycerophosphate Positive 115 
Ceramide Positive 264 
Hexosylceramide Positive 264 
 
Positive 180 
Lactosylceramide Positive 264 
 
Positive 180 
Sphingomyelin Positive 184 
 
Negative 168 
Cholesterol ester Positive 369 
Cholesterol (as acetate) Positive 77 
 
Table 2.2. Examples of scanning modes in lipidomics.73 
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The mass analyzers frequently employed in lipidomics are Time-of-Flight, Ion 
Trap, Triple-Quadrupole, and Fourier Transform Ion Cyclotron Resonance.74 Proper 
selection of the mass analyzer depends on the resolution, mass range, scan rate, and 
detection limit required for an application.  
Triple-Quadrupole mass spectrometers provide quantitative analyses of high 
precision and accuracy using the multiple reaction monitoring (MRM) mode.75 The main 
drawback of all quadrupole instruments is their low resolving power and limited mass 
precision and accuracy in m/z measurement for global identification of lipids. Some of 
these disadvantages are overcome by various hybrid instruments. The so-called Qq-TOF 
instruments, in which Q3 is replaced by a TOF, have been employed to improve resolving 
power for product ions in MS/MS mode and allows more precise m/z determinations for 
lipids.76 
Fourier transform mass spectrometers are the highest resolution and mass accuracy 
for lipids have been obtained using FT-ICR mass spectrometers and hybrid instruments 
that use them as product analyzer (e.g., LIT-FT).77 The further coupling of these 
instruments to HPLC-ESI makes possible the analysis of complex lipid mixtures.78,79 FT-
ICR instruments, however, are expensive and quite laborious when it comes to operation 
and maintenance. 50,51 
Hybrid mass spectrometers combining different types of mass analyzers (e.g., 
quadrupole linear ion trap, quadrupole TOF and linear ion trap-orbitrap), are regularly used 
in lipid identification and quantification.80,81  
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Hybrid TOF instruments have been extensively used for lipidomic analysis.80 The 
main advantages of hybrid TOF instruments include duty-cycle related sensitivity, high 
speed which facilitates tandem mass with liquid chromatography, and excellent mass 
accuracy. This is essentially important when speed and sensitivity are simultaneously 
necessary, such as in tandem mass spectrometry. 
Ion Trap mass spectrometers offer good sensitivity and high throughput. However, 
these instruments suffer from low dynamic range, and space-charge effects that limit the 
number of ions that can be stored at any one time.82 Recent developments in the ion-trap 
family of mass analyzers, have made higher resolution and expanded dynamic range 
possible.83 The Orbitrap mass spectrometer is a newer member of the ion trap type 
instruments which have been largely employed for high-quality lipidome identification and 
quantification with high mass accuracy and resolving power.77  
The work described in Chapter 3 evaluates the performances of high resolution 
quadrupole time of flight (Q-TOF) and Orbitrap (Velos) mass spectrometers for untargeted 
lipidomic analysis. The schematic of these instruments are depicted in Figure 2.4. 
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Figure 2.4. Schematic diagram of the Synapt84 (A) and Orbitrap85 (B) instruments. 
 
2.4. Data Processing for Mass Spectrometry Based Lipidomics 
 
The handling, processing, analysis and integration of massive data generated by 
LC/MS require specialized mathematical, statistical and bioinformatics tools.86 One of the 
ongoing challenges of LC/MS metabolomics is the development of better data processing 
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methods.87 Typical data processing workflow for the data generated by LC/MS approaches 
usually proceeds through multiple universal stages, including filtering, feature detection, 
alignment and normalization (Figure 2.5). 
 
Figure 2.5. Summary of metabolomic data processing workflow.88 
Filtering methods process the raw signal with aim of removing both chemical and 
random noise. Feature detection is an important step used to measure all signals caused by 
true ions and avoid detection of false positives. Alignment is needed for correcting 
retention time differences between multiple runs and combining data across different 
samples. Normalization steps remove the unwanted systematic variation in ion intensities 
between measurements, while retaining the interesting biological variation.89  
Due to its complex nature, non-targeted lipidomics data processing has to be linked 
to advanced chemometric techniques, to reduce the data complexity into a smaller set of 
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manageable signals.90 A major challenge lies in removing artifacts otherwise mistakenly 
interpreted as real lipids from large mass spectrometry data files. In addition, interpretation 
and translation of results into a biologically-useful meaning make identification and 
quantification imperative. Despite the improvements, several caveats still remain and a 
single workflow does not provide a perfect solution in terms of robust cleanup of all 
lipidomic datasets. Figure 2.6 shows a data processing workflow developed and utilized in 
the Arriaga group to automate data cleanup and peak finding and to putatively identify the 
resulting genuine ions. The developed workflow is comprised of the following: (1) 
untargeted UPLC/MS analysis of the biological systems of interest; (2) application of 
bioinformatics tools to identify candidate features characteristic of these systems; (3) 
confirmation of candidate features via evaluation of extracted ion chromatograms (XICs); 
(4) identification using online database searching; (5) mass accuracy confirmation and 
evaluation of fragmentation patterns. Application of this workflow results in more reliable, 
higher confidence preliminary identifications over a wide range of biological systems.  
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Figure 2.6. Workflow for preliminary identification of lipids from LC/MS.91 
A number of software packages have been recently developed to meet the 
challenges of metabolomics data processing. Each program uses different algorithm, 
however they all aim to limit the number of false-positive peaks, while retaining true lipids. 
Available software tools are divided into two commercial and freely available categories 
which use various statistical tools to interpret a matrix containing peak intensities. Table 
2.3 includes a list of the most commonly used tools for LC/MS metabolomics data analysis. 
In the work described in Chapter 3, five different software programs were compared to 
determine their effectiveness at analyzing untargeted datasets for lipidomics. These include 
the two vendor softwares (MassLynx and Xcalibur) as well as XCMS, Progenesis, and 
LipidSearch. Some aspects to consider in choosing the software for metabolomic data 
processing are quality of processing, ease of use, performance and overall cost of the 
software.92  
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Tool Type Reference 
MetaboAnalyst 
 
Web Xia et al, 2012 
XCMS R Smith et al, 2006 
MetSign MatLab Lommen and Kools, 2012 
MAVEN Application Melamud et al, 2010 
mzMine Application Pluskal et al, 2010 
MetDAT Web Xia et al, 2009 
MetAlign Web Lommen and Kools, 2012 
mzMatch R Scheltema et al, 2011 
OpenMS Web Bertsch et al, 2010 
Table 2.3. Common tools available for LC/MS metabolomics data processing. 
 
  
 27 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3: Comparison of High Resolution Quadrupole-Time-of-Flight and LTQ-
Orbitrap Mass Spectrometers for Lipidomic Analyses  
 28 
 
Lipidomic studies have increased exponentially over the last decade owing to the 
vital roles that lipids play in human physiological and pathological processes. However, 
because of the diversity and complexity of lipids, lipid analysis is still full of challenges. 
The recent developments of mass spectrometry technology methods greatly push forward 
the study of lipids in biological matrices. The benefits of high resolution mass spectrometry 
are well known and widely realized in various lipidomics applications.93 However, 
comparisons between high resolution mass spectrometers for a comprehensive analyze 
lipids is not common place. Here, several analytical figures of merit are calculated to 
compare the performance of high resolution quadrupole time of flight (Q-TOF) and linear 
trap quadrupole-Orbitrap (LTQ-Orbitrap) mass spectrometers for untargeted lipidomic 
analysis of the post nuclear fractions (PNFs) of a mouse myoblast cell line. Both mass 
spectrometers are compared in terms of number of identifications, accuracy, resolution, 
reproducibility and signal-to-noise ratio. The output data are analyzed using XCMS, 
Progenesis94, LipidSearch95, Xcalibur96, and MassLynx89 to determine the software that 
provides the highest number of hits from the data analysis workflow.  
Overall, both instruments show adequate mass accuracies (< 3ppm) allowing high 
confidence identifications of metabolites. The Q-TOF (Synapt G2) shows higher signal to 
noise ratio leading to enhanced sensitivity than the LTQ-Orbitrap (Velos) in positive 
ionization mode. The LTQ-Orbitrap has better mass resolution below 700 m/z, while the 
Q-TOF has better resolution above 700 m/z. Reproducibility of the peak intensities was 
better on the Synapt in both positive and negative electrospray mode. Our results support 
the use of the Q-TOF when lipids of interest are in low abundance and the use of the LTQ-
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Orbitrap when detecting lipids with higher molecular mass. Overall, the use of Synapt G2 
Q-TOF is recommended here for unbiased lipidomics and metabolomics analyses.  
3.1. Introduction  
 
 Untargeted metabolomics is an emerging approach for the simultaneous analysis of 
intracellular metabolites in complex systems.73 Metabolomics holds the promise to 
extensively contribute to the discovery of biomarkers of diseases in medical diagnostics, 
or evaluation of the alterations caused by environmental stressors or pharmacological 
influences.97 Liquid chromatography coupled to mass spectrometry (LC/MS) have allowed 
metabolomics to become a fast growing field and is often the method of choice for global 
analysis of compounds in biological systems.98 The comprehensive investigation of the 
metabolome is challenging due to its enormous complexity and dynamics.99 
Particularly because of a wide range of metabolite concentrations in biological fluids, 
different physiochemical properties, and the diversity of molecular species including small 
molecules, lipids, vitamins, simple amino acids and peptides.100 Employing high resolution 
mass analyzers with high sensitivity, selectivity, and mass accuracy is necessary to 
determine the abundance and characterize the structure of metabolites in complex 
mixtures.101 
The role of MS in metabolic profiling is evolving constantly, as both 
instrumentation and software becomes more sophisticated and researchers realize current 
technological capabilities. Development and improvement of mass analyzers, including the 
hybrid Quadrupole-time of flight (Q-TOF), Fourier transform ion cyclotron resonance 
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(FTICR), and Orbitrap has provided the ability to acquire more accurate and specific 
biological information in relatively high-throughput experiments.102 Despite recent 
technological advancements in all mass spectrometry techniques, no single analytical 
platform or approach exists for untargeted metabolomics, all having advantages and 
limitations. The advantages and limitations of the different mass spectrometry platforms 
have been extensively reviewed elsewhere.103,104 It is known that time of flight instruments 
often yield different mass spectrometry results from ion trap mass spectrometers due to 
their different design and operation modes. The hybrid Orbitrap and TOF instruments are 
the most widely used mass spectrometry platforms in metabolomics. Features of these 
instruments at their present stage of development include high mass resolution, high 
sensitivity, as well as high mass accuracy in regards to obtaining molecular and product 
ion spectra.  
It is important to highlight that the challenge of metabolite identification is still a 
significant bottleneck in untargeted mass spectrometry analysis.87 The massive amounts of 
information generated by LC/MS based experiments require specific data analysis 
strategies. Over the past decade significant innovations were observed and several software 
tools were successfully developed to facilitate MS based metabolomic data processing.86,87 
These programs operate differently due to differences in the algorithms used to identify 
and align peaks.  
Herein, we conducted a comparison of a Synapt G2 quadrupole-TOF mass 
spectrometer (Q-TOF) and an LTQ-Orbitrap Velos (LTQ-Orbitrap) (see Chapter 2), both 
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coupled to LC systems. Metabolites from a post nuclear fraction of mouse myoblast cell 
line were extracted using sample preparation protocols that preferentially extracts lipids. 
Following reverse-phase LC/MS, the data derived from the two mass spectrometers were 
thoroughly examined with Masslynx 4.1 and Xcalibur 2.2 software as well as with 
XCMS105 open source software. Performances of Q-TOF and Orbitrap mass analyzers have 
been previously compared for plant metabolomic analyses106 and targeted drug discovery 
metabolite screening,107 but not in the context of lipidomics. In present study, we compared 
mass accuracy, mass resolution, signal to noise ratio, and sensitivity of a Q-TOF (Synapt 
G2) and an LTQ-Orbitrap (Velos) in the analysis of complex biological samples enriched 
in lipids. Overall, both instruments showed adequate mass accuracies (< 3 ppm for all 
measured compounds), however mass accuracy values were statistically higher for most of 
the lipid standards on the Synapt. Signal to noise were higher on the Synapt, which is an 
advantage in detecting the low abundance metabolites in biological matrices. 
Reproducibility associated with the peak intensities was better on the Synapt, with 79% of 
metabolites exhibiting a median CV of < 30% in positive ESI mode compared to 55% on 
the Orbitrap. The overall sensitivity was similar for both mass spectrometers using XCMS 
platform, though the LTQ-Orbitrap proved slightly more sensitive for certain compounds 
in negative ESI mode. Resolution on the Q-TOF was better for m/z > 700, while the LTQ-
Orbitrap had better resolution for m/z < 700. 
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3.2. Materials and Methods 
 
3.2.1. Reagents 
 
The solvents used for extraction were HPLC grade chloroform and methanol from 
Fisher Scientific (Fairlawn, NJ). Dubelco's Modified Eagle Medium (DMEM) high glucose cell 
medium, and fetal bovine serum were from Thermo Scientific (Waltham, MA). Phosphate 
buffered saline (PBS, 10× concentration, 1.37 M NaCl, 27 mM KCl, 80 mM Na2HPO4, 
and 20 mM KH2PO4, pH 7.4) was obtained from Bio-Rad (Hercules, CA). 0.5% trypsin-
EDTA (10× concentration, no phenol red) was obtained from Life Technologies (Grand 
Island, NY). Sucrose, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 
mannitol, ethaminetetraacetic acid (EDTA) were obtained from Sigma-Aldrich (St. Louis, 
MO). Cell homogenization buffer consisted of 70 mM sucrose, 215 mM mannitol, 4.31 
mM HEPES, and 4.94 mM EDTA, pH 7.4. Water was purified with a Millipore Synergy 
UV system (18.2mΩ/cm, Bedford, MA). Ultra LC/MS-grade methanol, acetonitrile, and 
water were from Formic acid was from EMD (Darmstadt, Germany). Standards including: 1,2-
distearoyl-sn-Glycero-3-Phosphoethanolamine, 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine, 1-stearoyl-2-hydroxy-sn-glycero-3-phosphocholine, 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphate, 1-palmitoyl-2-oleoyl-sn-glycerol, D-erythro-sphingosine-1-phosphate, 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphoinositol, and 1',3'-bis[1,2-dimyristoyl-sn-glycero-3-
phospho]-sn-glycerol, were purchased from Avanti Polar Lipids (Alabaster, AL). Cholesterol, 
L-α-phosphatidylcholine, C18:1 ceramide (d18:1/18:1(9Z)), and L-α-phosphatidyserine were 
purchased from Sigma Aldrich (St. Louis, Mo). 
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3.2.2. Sample Preparation and Extraction 
 
C2C12 cells (mouse myoblast cell line) were cultured in a T75 flask for 48 hours 
at 37 °C, 5% CO2 in DMEM supplemented with 10% fetal bovine serum containing 110 
µg/mL gentamycin. Cells were lifted with trypsin in PBS (0.5% v/v) after 90% confluency 
was reached and then split 1:20 (v/v) into new flasks. Cells were harvested by differential 
centrifugation at 600g for 10 minutes at 4 °C and then washed once by suspending in 
homogenization buffer and differential centrifugation at 1,000g for 10 minutes. Cell 
disruption was done in an ice-cooled cell disruption bomb (Parr Instrument Co., Moline, 
IL) charged to 500–600 psi with nitrogen gas for a minimum of 15 min prior to pressure 
release. The lysate was collected in a 50-mL falcon tube and then centrifuged at 1,000g for 
10 min to pellet unbroken cells and nuclei. The post nuclear fraction (the supernatant) was 
removed and collected to a clean microcentrifuge tube. All steps were performed on ice or 
at 4 °C. 
To extract the lipids, a previously published protocol was used.108 Briefly, 3.75 ml 
of ice cold chloroform: methanol 1:2 v/v was added to 1 ml of the collected fraction and 
vortexed for 2 min. Sample was treated with 1.25 ml of chloroform and vortexed for 1 min. 
Subsequently, 1.25 ml of water was added to the sample and vortexed for 1 min. Sample 
was centrifuged in glass tubes at 13,000g for 10 min to pellet any non-extracted materials. 
The upper phase containing salts and other water soluble metabolites were removed and 
protein phase was pierced with a pipette tip and discarded. The organic phase (lower phase) 
was collected and transferred to a new siliconized 0.6 ml Eppendorf tube and evaporated 
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overnight at room temperature under vacuum to remove extraction solvents. Tubes were 
filled with nitrogen to remove any air and stored dry at -80 °C prior to analysis.  
3.2.3. LC/MS Conditions  
 
The pellet recovered from the Bligh and Dyer extraction was resuspended in 200 μL 
1:1:1 HPLC-grade MeOH : CHCl3 : H2O with a syringe, vortexed for 30 s, and incubated for 5 
min. The samples were centrifuged at 16,100g for 5 min to remove any non-resuspended 
materials.  
Twelve pure lipid standards were purchased and stock solutions were prepared in 
HPLC-grade MeOH :  CHCl3 1 : 1 v/v at a final concentration of 1 mg/mL. Standards were 
mixed from their stocks to a final concentration of 50 μg/mL and vortexed for 1 minute. 
Standards samples were added to mass spectrometry sample tubes from Microsolv Technology 
Corporation (Leland, NC) for analysis on both MS platforms. Standard mixture was then spiked 
from the stock into post-nuclear fraction of C2C12 cells at two different stages, to the fraction 
prepared with nitrogen cavitation prior to Bligh and Dyer lipid extraction, and to the 
reconstituted pellet right before the LC/MS analysis.91 Standards were spiked at a final 
concentration of 50 μg/mL.  
The two mass spectrometers were coupled to different LC systems operated at different 
flow rates, while still using the same mobile phase composition and gradient conditions. The 
Synapt G2 HDMS Q-TOF was coupled to Waters Acquity UPLCTM system and the reversed-
phase column used was a Waters HSS T3 C18, 2.1 mm × 100 mm column (1.7 μm diameter 
particles). The Orbitrap Velos was paired with Thermo Scientific UHPLC pump and a Dionex 
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UHPLC C18, 0.5 mm × 100mm (1.8 μm diameter particles) was used at a temperature of 45 
°C. The following 16 min linear gradient separations were employed at a flow rate of 400 
µL/min on the Q-TOF and 10 µL/min on the Orbitrap using a binary mobile phase system 
where A: Methanol:Water, 60:40 v/v, 10mM ammonium acetate, containing 0.1% formic acid 
and B: Methanol:Isopropanol 10:90 v/v, 10mM ammonium acetate, containing 0.1% formic 
acid. The gradient profile was: 40% B, 0 min to 5 min; 40% B to 100% B, 5 min to 13 min; 
100% B, 13 min to 16 min.  
The Synapt G2 instrument was calibrated with 2 µg/µl Sodium iodide solution in 50/50 
2-propanol/Water. Simultaneous low- and high-collision energy (CE) mass spectra were 
collected in centroid mode over the range m/z 50–1200 every 0.2 s during the chromatographic 
separation. Samples were analyzed in high-definition MSe mode (HDMSe) and the TOF 
analyzer was operated in the V resolution mode. MSe parameters in positive electrospray 
ionization mode were as follows: capillary, 0.3 kV; sampling cone, 35.0 V; extraction cone, 5.0 
V; desolvation gas flow, 800 L/h; source temperature, 100 °C; desolvation temperature, 20 °C; 
cone gas flow, 20 L/h; trap CE, off (low CE collection), trap CE ramp 15–65 V (high CE 
collection); lockspray configuration used the average of three m/z measurements (0.2 s 
scan, m/z 100–1200, every 10 s) of protonated leucine-enkephalin (m/z 556.2771) formed from 
infusion of a 5 μg mL−1 solution. All MSe parameters were identical in negative ionization mode 
except the following: capillary, 2.5 kV; sampling cone, 30.0 V; extraction cone, 4.0 V.  
The LTQ-Orbitrap Velos instrument was calibrated with Polysiloxane solution and 
mass accuracy was calculated based on the background ions including 371.10124 m/z. Mass 
spectra were recorded from m/z 200-2000 with a spray voltage of 3.5 kV and 3.10 kV in 
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positive and negative ion mode respectively. The sheath and auxiliary gas flows (both 
nitrogen) were optimized at 50 and 0 arbitrary units (a.u.), respectively. Capillary 
temperature was set to 300 °C. Automatic gain control (AGC) target value was set at 
1 × 106 charges and maximum injection time was set to 100 ms, and the gate lens offset to 
90 V and -90 V in positive and negative electrospray. The mass spectra were acquired in 
the profile mode and external calibration was applied. MS2 fragmentation with no 
precursor ion selection was performed with normalized collision energy set to 35% with a 
ramp of 50% and nitrogen was used as collision gas. The resolution was set at 70,000 at 
m/z = 200.  
3.2.4. Data Treatment 
 
Raw data files collected on the Q-TOF (Synapt G2) and LTQ-Orbitrap (Velos) were 
initially processed by the individual manufacturer software including MassLynx 4.1 
(Waters) and Xcalibur 2.2 (Thermo Fisher Scientific) for mining chromatographic and 
mass spectrometric data. Additional software packages used for data processing include: 
Progenesis QI, LipidSearch, and XCMS Online.109 These software packages have been 
effective for feature detection and perform pre-processing steps, such as data reduction, 
noise filtering, background subtraction, mass calibration and retention time alignment.110 
Relative mass accuracies were calculated by dividing the mass error by the 
theoretical m/z values for the standard samples that were commonly detected on both 
platforms and are expressed in parts per million (ppm). Resolution was calculated by taking 
the ratio of peak mass to the peak width at half maximum intensity. Signal to noise values 
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were calculated by dividing the peak signal intensities by an estimated noise level. Noise 
was calculated as the standard deviation of the baseline over a selected window before the 
peak. Reproducibility in signal intensity was measured as the average relative standard 
deviation (n=3) for the intensities of all the peaks observed in the MS spectra. 
The raw mass spectrometric file types from both instruments were processed by 
XCMS online software (xcmsonline.scripps.edu). Raw data acquired by two platforms 
were converted to .mzXml common data format using Proteowizard File converter 
(proteowizard.sourceforge.net) and the following parameters used in this analysis: (i) 
Feature detection: centWave method, min. and max. peak width = 5 and 20, S/N 
threshold = 6, mzdiff = 0.01, integration method = 1, prefilter peaks = 3, prefilter 
intensity = 100, Noise filter = 0; (ii) Retention time correction: Obiwarp method, 
profStep = 1; (iii) Alignment: mzwid = 0.015, bw = 5, minfrac = 0.5, max = 100, 
minsamp = 1. The data were processed for peak detection, retention time correction, 
chromatographic alignment, statistical analysis, and identification through METLIN 
database. The identifications include possible adducts, fragments and isotopes. The results 
output includes XICs, boxplots, cloud plots, and principal component analysis (PCA) for 
sample discrimination.  
Preliminary identification of features by XCMS was based on a previous 
workflow,105,109 consisting of 5 steps: (1) LC/MS profiling of the biological systems of 
interest; (2) chemometric analysis to determine characteristic/unique hits of different 
biological groups; (3) manual evaluation of extracted ion chromatograms (XICs) referred 
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to as Checkpoint 1; (4) structural database searching; (5) mass accuracy confirmation and 
evaluation of fragmentation patterns from tandem mass spectra referred to as Checkpoint 
2. Extracted ion chromatograms (XICs), were manually examined to confirm identified 
features by having a true chromatographic peak profile, referred to as Checkpoint 1 in the 
workflow (see Chapter 2). Fragmentation patterns of each feature were evaluated by 
comparison of high-collision energy (MS2) mass spectra with simulated fragmentation 
patterns calculated in silico using METLIN software, referred to as Checkpoint 2 (see 
Chapter 2). 
In addition to XCMS, Progenesis QI (Nonlinear Dynamics, Newcastle, UK) was 
used to search for compounds in ChemSpider and Progenesis MetaScope databases.94 
Default parameters included m/z hits within a 5 ppm tolerance and a score value above 
30.111,112 The statistical output of univariate (cloud plots) and multivariate (PCA plots) data 
analysis were generated by adjusting the threshold and range of the parameters mentioned 
elsewhere.113 Identifications for each database were combined and counted after 
elimination of redundancies. 
In addition to XCMS, LipidSearch60 (version 4.1, Thermo Fisher Scientific) was 
used for lipid identification of the data collected on the Orbitrap. This software uses a 
database search of precursor accurate masses and their predicted fragment ions. The 
following parameters were used in this analysis: precursor mass tolerance = 5 ppm, product 
mass tolerance = 5 ppm, relative product intensity threshold = 1, m-score threshold = 2, 
retention time tolerance = 0.2 min, retention time range = 0-20 min. 
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3.3. Results  
 
This study compared the analytical performance of a Q-TOF and an LTQ-Orbitrap 
by analyzing lipid standards and metabolites in a post nuclear fraction (PNF) of a mouse 
myoblast cell line. Mobile phase compositions and gradient profiles were identical to 
minimize the effect of chromatographic differences on the data. Raw data from the Q-TOF 
and the LTQ-Orbitrap were (1) low- and high-collision energy mass spectra (MSe) and (2) 
MS1 and MS2 spectra, respectively.  
The initial comparison used twelve lipid standards. Lipid standards were run on 
both MS platforms and typical extracted ion chromatograms and MS profiles are shown in 
Figure 3.1. The results are obtained using positive ESI, for 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine with m/z 759.5780. Although the chromatographic conditions 
were matched, columns were different which resulted in expected differences in 
chromatographic retention times (Figure 3.1 A and B). The exact mass and fragment ions 
demonstrate differences resulting from using different types of mass spectrometers. 
MS/MS fragmentation using the LTQ-Orbitrap gives a fragment at m/z 672 which 
corresponds to the loss of ethyltrimethylammonium (C5H14N+) with a molecular weight of 
88 g/mol. In contrast, high energy MS on the Q-TOF gives a unique fragment at m/z 184 
which corresponds to the loss of the protonated phosphatidylcholine head group.  
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Figure 3.7. Representative data for m/z 759.5780. Structure of standard 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine (A); Extracted ion chromatogram and mass spectrum obtained on the LTQ-Orbitrap (B); and 
on the Q-TOF instruments (C). 
The second comparison was based on analysis of post nuclear fractions (PNFs) of 
a mouse myoblast cell line, which displays the expected complexity of a biological sample. 
This comparison included reproducibility in signal intensity, mass resolution, and signal-
to-noise ratio detected peaks that pass Checkpoint 1 (See Section 3.2.4).  
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3.3.1. Reproducibility 
 
Reproducibility of ion intensity was based on the analysis of technical replicates, 
after Checkpoint 1. For Synapt in positive ion mode, the range for the coefficients of 
variation (CV) was between 0.1 – 76 %, ( average = 23, std. dev = 13, N = 3 technical 
replicates for all CV values included here). For Synapt in negative ion mode, the range for 
CV was between 11 – 95 %, (average = 30, std. dev = 11, N = 3 technical replicates for all 
CV values included here). For any of the two electrospray ionization polarities, CVs were 
not correlated with signal-to-noise ratio (Figure 3.2). For the LTQ-Orbitrap in positive ion 
mode, the coefficients of variation (CV) was between 1.1 - 149 %, (average = 53, std. dev 
= 42, N = 3 for all CV values included here). For the LTQ-Orbitrap in negative ion mode 
CV range was between 0.4 - 104 %, (average = 27, std. dev = 22, N = 3 for all CV values 
included here). For any of the two electrospray ionization polarities, CVs were not 
correlated with signal-to-noise ratio (Figure 3.3).  
Overall, when comparing the mean CV values in positive ESI, 79% and 55% of the 
metabolites showed a mean CV of <30% (a level generally considered acceptable with 
respect to laboratory error) on the Synapt and Orbitrap respectively.114 In negative ESI, 
73% and 58% of the metabolites showed a mean CV of <30% on the Synapt and Orbitrap 
respectively.. 
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Figure 3.8. Reproducibility in technical replicates analyzed on the Q-TOF instrument. Positive ionization 
mode (A); Negative ionization mode (B). 
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Figure 3.9. Reproducibility in technical replicates analyzed on the LTQ-Orbitrap instrument. Positive 
ionization mode (A); Negative ionization mode (B). 
3.3.2. Mass Accuracy  
 
High mass accuracy is needed for identification and structural characterization of 
unknown compounds.115 Twelve lipid standards were used to determine mass accuracy of 
each instrument, but not all were detected (Figure 3.4). In positive ion mode, 1-stearoyl-2-
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hydroxy-sn-glycero-3-phosphoethanolamine, 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine, and 1-stearoyl-2-hydroxy-sn-glycero-3-phosphocholine were detected by 
both instruments (Table 3.1.A). In negative ionization mode, seven compounds were 
detected on both the Q-TOF and LTQ-Orbitrap instruments and four standards were not 
detected at all (Table 3.1.B). The standard 1',3'-bis[1,2-dimyristoyl-sn-glycero-3-
phospho]-sn-glycerol was never detected on any of the two mass spectrometers in positive 
or negative ion mode. A summary of the mass accuracies calculated in positive and 
negative ESI is shown in Table 3.1.  
In general, the overall measured masses differed from the calculated monoisotopic 
masses by less than 3 ppm on both instruments. Mass accuracy was 0.6 ± 0.5 ppm (average 
± SD, n=3 technical replicates) ppm and 1.7 ± 0.3 ppm (average ± SD, n=3 technical 
replicates) for species detected under positive ion mode in the Q-TOF and the LTQ-
Orbitrap, respectively. Similarly, mass accuracy was 1.3 ± 0.5 ppm (average ± SD, n=3 
technical replicates) ppm and 1.8 ± 0.5 ppm (average ± SD, n=3 technical replicates) for 
species detected under negative ion mode in the Q-TOF and the LTQ-Orbitrap, 
respectively. A t-test was performed on the individual mass accuracies of individual m/z 
values in positive and negative ESI. Results show that the differences are statistically 
significant (p = 0.02, p = 0.04) for compound 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine (Compound C, Figure 3.4) and 1-stearoyl-2-hydroxy-sn-glycero-3-
phosphoethanolamine (Compound F, Figure 3.4) in positive ESI data (Table 3.1 A). 
Similarly, a t-test results show a significant difference (p < 0.05) in negative ESI data for 
C18:1 Ceramide (d18:118:1(9Z)) (Compound B, Figure 3.4), 1-palmitoyl-2-oleoyl-sn-
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glycero-3-phosphocholine (Compound C, Figure 3.4), 1-stearoyl-2-hydroxy-sn-glycero-3-
phosphocholine (Compound D, Figure 3.4), and 1-palmitoyl-2-oleoyl-sn-glycerol, 
(Compound G, Figure 3.4). The rest of the comparisons are not significantly different 
(Table 3.1 B). 
 
 46 
 
Figure 3.10. Lipid standards used to compare performance of Q-TOF and LTQ-Orbitrap. (A) D-erythro-
sphingosine-1-phosphate, (B) C18:1 Ceramide (d18:118:1(9Z)), (C) 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine, (D) 1-stearoyl-2-hydroxy-sn-glycero-3-phosphocholine, (E) 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphoinositol (ammonium salt), (F) 1-stearoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine, 
(G) 1-palmitoyl-2-oleoyl-sn-glycerol, (H) L-α-Phosphatidylcholine, (I) 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphate, (J) L-α-phosphatidylserine (sodium salt), (K) Cholesterol, (L) 1',3'-bis[1,2-dimyristoyl-sn-
glycero-3-phospho]-glycerol (sodium salt). 
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(A). Positive ESI 
Accuracy, ppm (±SD) 
Q-TOF LTQ-Orbitrap 
1-stearoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine (m/z 747.5780)* 0.29 (0.13) 1.83 (0.21) 
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (m/z 759.5780)* 0.41 (0.02) 2.17 (0.25) 
1-stearoyl-2-hydroxy-sn-glycero-3-phosphocholine (m/z 523.3640) 0.96 (0.90) 0.95 (0.49) 
 
(B). Negative ESI 
Accuracy, ppm (±SD) 
Q-TOF LTQ-Orbitrap 
1-stearoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine (m/z 747.5780) 0.76 (0.64) 0.89 (0.38) 
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (m/z 759.5780)* 0.61 (0.21) 2.36 (0.24) 
1-stearoyl-2-hydroxy-sn-glycero-3-phosphocholine (m/z 523.3640)* 1.37 (0.56) 1.75 (0.41) 
1-palmitoyl-2-oleoyl-sn-glycerol (m/z 620.5380)* 1.22 (0.46) 2.10 (0.38) 
D-erythro-sphingosine-1-phosphate (m/z 379.2490) 1.21 (0.16) 1.45 (0.25) 
C18:1 Ceramide (d18:1/18:1(9Z)) (m/z 563.5280)* 1.49 (0.76) 1.81 (0.76) 
L-α-Phosphatidylcholine (m/z 767.9999) 2.42 (0.51) 2.62 (0.67) 
 
Table 3.4. Mass accuracies of lipid standards analyzed using the Q-TOF and the LTQ-Orbitrap instruments. 
(A) Positive ionization mode. (B) Negative ionization mode. Reported values (ppm) are mean of 3 replicates 
(±SD). Only standards that detected commonly on both instruments are shown here. Compounds with 
statistically different accuracies (p < 0.05) are marked with an asterisk.  
 
3.3.3. Mass Resolution 
 
High mass resolution is essential to distinguish among compounds with similar 
molecular masses, which are common place in complex biological mixtures. Including the 
mass resolution of all peaks detected in the analysis of PNF, the LTQ-Orbitrap had an 
average resolution of 7.4 x 104 and 6.3 x 104 in positive and negative ionization modes, 
 48 
 
respectively. The Q-TOF had an average resolution of 4.3 x 104 and 4.2 x 104 in positive 
and negative ionization modes, respectively. Further examination of resolution as a 
function of m/z revealed opposite trends in resolution as a function of m/z (Figure 3.5). For 
the Q-TOF resolution increased when m/z increases. For the LTQ-Orbitrap resolution 
decreased when m/z increases. In summary, the LTQ-Orbitrap had higher mass resolution 
from 200 to 700 m/z, while the Q-TOF had higher mass resolution from 700 to 1200 m/z.  
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Figure 3.11. Mass resolution comparison. (A) Positive ionization mode. (B) Negative ionization mode. Using 
the LTQ-Orbitrap, n = 44 and 36 for positive and negative ionization modes, respectively. Using the Q-TOF, 
n = 81 and 182 for positive and negative ionization modes, respectively. 
 
3.3.4 Signal to Noise Ratio 
 
The signal-to-noise ratio (S/N) of a mass spectrometer defines the ability to detect 
low abundance species, which are present in complex biological samples. The comparison 
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of S/N values of species detected in both LTQ-Orbitrap and Q-TOF was based on (1) the 
analysis of twelve lipid standards (Table 3.2, Figure 3.4) spiked into PNFs and (2) 
comparisons between peaks detected in both the LTQ-Orbitrap and Q-TOF when analyzing 
the same PNF. A summary of the signal to noise values calculated in positive and negative 
ESI is shown in Table 3.2.  
As an example, the S/N for 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine 
standard (m/z 759.5780) spiked into PNF in positive ionization mode was 6.8 ± 0.3 and 4.9 
± 0.2 (average ± SD, n = 3 technical replicates) for analysis done on the Q-TOF and LTQ-
Orbitrap, respectively. The S/N for the same compound in negative ionization mode was 
29.0 ± 0.5 and 99.0 ± 0.5 (average ± SD, n = 3 technical replicates) for analysis done on 
the Q-TOF and LTQ-Orbitrap, respectively. 
Another example shows the S/N for 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine standard (m/z 747.5780) in positive ionization mode was 8.0 ± 0.3 
and 9.0 ± 0.7 (average ± SD, n = 3 technical replicates) on Q-TOF and LTQ-Orbitrap, 
respectively. The S/N for the same compound in negative ionization mode was 18.0 ± 0.3 
and 21.0 ± 0.5 (average ± SD, n = 3 technical replicates) for analysis done on the Q-TOF 
and LTQ-Orbitrap, respectively. 
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(A). Positive ESI 
Signal to Noise, ppm (±SD) 
Q-TOF LTQ-Orbitrap 
1-stearoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine (m/z 
747.5780)* 
8.02 (0.32) 9.43 (0.73) 
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (m/z 759.5780) 6.88 (0.31) 4.96 (0.21) 
1-stearoyl-2-hydroxy-sn-glycero-3-phosphocholine (m/z 523.3640) 6.12 (0.43) 5.41 (0.91) 
 
(B). Negative ESI 
Signal to Noise, ppm (±SD) 
Q-TOF LTQ-Orbitrap 
1-stearoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine (m/z 747.5780) 
18.62 (0.33) 21.18 (0.53) 
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (m/z 759.5780)* 
29.28 (0.54) 99.25 (0.52) 
1-stearoyl-2-hydroxy-sn-glycero-3-phosphocholine (m/z 523.3640) 
32.73 (0.71) 39.64 (0.11) 
1-palmitoyl-2-oleoyl-sn-glycerol (m/z 620.5380)* 
27.96 (0.37) 18.02 (0.23) 
D-erythro-sphingosine-1-phosphate (m/z 379.2490) 
49.06 (0.35) 40.24 (0.83) 
C18:1 Ceramide (d18:1/18:1(9Z)) (m/z 563.5280)* 
31.08 (0.65) 47.53 (0.74) 
L-α-Phosphatidylcholine (m/z 767.9999)* 
19.83 (0.45) 47.27 (0.14) 
 
Table 3.5. Signal to noise values of lipid standards analyzed using the Q-TOF and the LTQ-Orbitrap. (A) 
Positive ionization mode. (B) Negative ionization mode. Reported values (ppm) are mean of 3 replicates 
(±SD). Only standards that detected commonly on both instruments are shown here. Compounds with 
statistically different S/N (p < 0.05) are marked with an asterisk.  
 
To compare the S/N values of peaks detected at the same m/z in both instruments, 
S/N values at each m/z were reported as a ratio of the value obtained with the Q-TOF over 
that obtained with LTQ-Orbitrap (Figure 3.6). Out of 528 features in positive ESI mode, 
344 features (65% of the features) had a relative S/N value higher than 1,177 features (34% 
of the features) had a S/N value lower than 1, and 7 features (1% of the features) had 
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relative S/N value of 1 (corresponding to zero in the log graph in Figure 3.6). Out of 89 
features in negative ESI mode, 67 features (75% of the features) had a relative S/N value 
higher than 1, 13 features (15% of the features) had a S/N value lower than 1, and 9 features 
(10% of the features) had relative S/N value of 1. These values show that signal to noise 
values were higher for the data collected on the Q-TOF, overall. Furthermore, a t-test was 
performed on the average signal to noise values in positive and negative ESI using both 
instruments. Compounds with statistically different S/N (p < 0.05) are marked with an 
asterisk in Table 3.2.  
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Figure 3.12. Relative signal to noise values. The S/N of peaks at a given m/z that were detected on both 
instruments and passed Checkpoint 1 (see Section 3.2.4) is plotted as their ratio (Q-TOF/LTQ-Orbitrap) on 
a log scale (y-axis). (A) Positive ionization mode (n= 528). (B) Negative ionization mode (n= 89). 
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3.3.5. Data Analysis 
 
Data processing and interpretation represent the most challenging and time‐
consuming steps in high‐throughput metabolomic experiments, regardless of the analytical 
platforms used for data acquisition.116 The software used for data analysis and search in 
databases influence the data outcomes, particularly in terms of discrimination between true 
and false positives. This study compared five commonly used programs in metabolite 
analysis: XCMS, Progenesis, LipidSearch, Xcalibur, and MassLynx117 in their ability to 
assign maximum number of potential molecular identities in databases based on the mass 
spectra of peaks that were selected through the workflow described in Section 3.2.4. 
Xcalibur and Masslynx were limited in platform versatility as they are only 
compatible with data analysis collected with the LTQ-Orbitrap (Velos) and the Q-TOF 
(Synapt G2), respectively (Figure 3.7). Xcalibur assigned 210 and 612 peaks to potential 
molecular identities in positive and negative ionization mode, respectively. Masslynx 
assigned 980 and 689 peaks to potential molecular identities in positive and negative 
ionization mode, respectively.  
Progenesis and XCMS were capable of analyzing data collected with both the LTQ-
Orbitrap (Velos) and the Q-TOF (Synapt G2) (Figure 3.7). Progenesis found 184 and 680 
potential molecular identities, under positive ionization mode, with the LTQ-Orbitrap 
(Velos) and the Q-TOF (Synapt G2), respectively. Under negative ionization mode, these 
two platforms showed 38 and 86 potential molecular identities, respectively. XCMS 
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assigned 68 and 664 peaks to potential molecular identities to data collected, under positive 
ionization mode, with the LTQ-Orbitrap (Velos) and the Q-TOF (Synapt G2), respectively. 
Under negative ionization mode, these two platforms assigned 335 and 32 peaks to 
potential molecular identities, respectively. The compatibility of XCMS with different 
analytical platforms and its ability to assign higher numbers of peaks to potential molecular 
identities are clear advantages to process data with either one of the instruments that were 
compared in this study.  
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Figure 3.13. Number of potential assignments to molecular identities using different software platforms. (A) 
Positive ionization mode. (B) Negative ionization mode. The number of potential assignments required 
processing of the raw data using the workflow described in Section 3.2.4. 
 
 
 
 57 
 
3.4. Discussion 
 
The goal of thisstudy was to compare two mass spectrometry platforms, LTQ-
Orbitrap and Q-TOF, to determine their suitability for unbiased analysis of compounds 
from lipid extracts of PNFs of a mouse myoblast cell line.  
Analysis of lipid standards was key to the comparison of the two platforms. As 
expected, not all the lipids were detected equally under positive and negative ion mode 
(Figure 3.4, Table 3.1). 
In positive ion mode, phosphatidylcholines (1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphocholine, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine) and 
phosphatidylethanolamine (1-stearoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine) 
were detected, as expected from their positive polar head group. Adducts of ceramides 
(C18:1 Ceramide (d18:118:1(9Z)), and neutral lipids (1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphoinositol, 1-palmitoyl-2-oleoyl-sn-glycerol, 1',3'-bis[1,2-dimyristoyl-sn-glycero-3-
phospho]-glycerol) might be detected as sodium and ammonium ions in positive ion mode, 
as reported previously in the literature.118,119 In our study, these species were not detected 
on either the Q-TOF or Orbitrap platforms. Lipids that were detected under negative ion 
mode included phosphatidylcholines (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine, 
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine), phosphatidylethanolamine (1-
stearoyl-2-hydroxy-sn-glycero-3-phosphoethanolamine), phosphatidylinositol (1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphoinositol), phosphatidylserine (L-α-
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phosphatidylserine), phosphatidylglycerol (1-palmitoyl-2-oleoyl-sn-glycerol), 
phosphatidic acid (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphate), ceramide (C18:1 
Ceramide (d18:1/18:1(9Z)), and sphingolipids (D-erythro-sphingosine-1-phosphate).  
As described in the results section, mass accuracy for 6 out of 10 lipid standards 
the Synapt had better mass accuracy than the LTQ-Orbitrap in both negative and positive 
ionization modes. The other four lipid standards were had statistically similar mass 
accuracy when compared across instruments. This observation is in agreement with 
previous reports.106 These findings are not surprising as mass accuracy is dependent on the 
design and operation modes unique to each instrument design. The narrow spread of the 
initial velocity in a TOF decreases uncertainty in the time-of-flight which results in 
accurate masses. In the Orbitrap, the frequencies of axial oscillation of each ion cause an 
image current with the same frequency that are transformed into m/z values.120 Error in the 
current image centroids, which is more prominent at low signal intensities, tends to 
introduce more error in mass accuracy that observed in TOF configurations.85,121  
It is worth noticing that our study used external mass calibration for both the Q-
TOF and the LTQ-Orbitrap. Further improvements in mass accuracy (< 1 ppm for Q-TOF 
and ~ 2 ppm for LTQ-Orbitrap) might be obtained with the use of internal calibration for 
each of these instruments, as reported elsewhere.122 Lastly, other hybrid Orbitraps 
(Exactive Plus) have been compared with the Q-TOF (Synapt G2) in terms of mass 
accuracy in a plant metabolomics study.106 The authors claimed that both instruments 
showed an average mass accuracy of < 2.5 ppm (m/z range= 100-1200) using external 
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calibration for all measured compounds. This is not surprising as it has been shown that 
the Q Exactive outperforms the LTQ-Orbitrap Velos in metabolome and proteome 
analyses.123  
There are currently no prospective studies comparing the reproducibility of peak 
intensities of TOF and Orbitrap based instruments. In this study, reproducibility of the peak 
intensities was calculated to establish the level of variation among technical replicates 
using two different mass spectrometers. Our data showed that Synapt outperformed the 
Orbitrap in reproducibility in both positive and negative ESI. Previous studies on the 
comparison between LTQ and high resolution Orbitraps showed that Orbitraps can produce 
more reproducible identifications than LTQs for analyzing lipids and proteins; however, 
the difference is not large.124  
Mass resolution was m/z dependent and better for the LTQ-Orbitrap below 700 m/z, 
while better for the Q-TOF above 700 m/z. These observations are consistent with the 
design of these mass analyzers. In Orbitrap mass analyzers, the axial frequency used to 
derive the m/z ratio is inversely proportional to the square root of m/z.85,125,126 Because axial 
frequency is independent of the initial properties of the ions, including kinetic energy or 
ion velocity, Orbitrap mass analyzers tend to have excellent mass resolution in the low m/z 
range.127 In TOF mass analyzers, mass resolution is related to differences in time of flight 
of ions with similar m/z and is directly proportional to the square root of m/z. At low m/z 
values the broadening in the time-of-flight dominates, compromising mass resolution.128 
At large m/z values, TOF mass analyzers tend to have superior resolution. 
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Detection and identification of low-abundance metabolites in complex biological 
samples presents major challenges in metabolomics studies. Signal to noise ratio is a key 
parameter to assess the detection capabilities of mass spectrometers which depends on the 
instrumentation design and performance. Our results indicated that higher values of the 
signal to noise ratio can be obtained on the Synapt G2.  Previous studies reported m/z 
dependent and compound specific differences comparing the performances of Orbitrap and 
QTOF instruments.106  
Background ions originating from solvent clusters generated by the electrospray 
ionization are considered a factor limiting the detection threshold (and noise) in TOF 
instruments.126 The effect of background ions on instrument noise is less relevant in 
Orbitrap instruments as Fourier transform-based filtering is used to remove the chemical 
background.129 On the other hand, overloading of the C-trap in Orbitrap instruments can 
cause ion suppression decreasing signal intensity, thereby decreasing the signal-to-noise 
ratio.130,131  
Existing computational tools are essential to assign molecular structures found in 
databases to experimental mass spectral data.132 Oftentimes the selection of such tool is 
defined by the analytical platform used to collect the data (e.g. Masslynx for Synapt and 
Xcalibur for Velos). Other computational resources are compatible with multiple 
platforms, such as Progenesis and XCMS used in this study. Overall XCMS provided more 
potential molecular identities assignments for both the Q-TOF (Synapt) and the LTQ-
Orbitrap (Velos) (Figure 3.7). Using XCMS to analyze the data resulted in different number 
of identifications from these two instruments. Different number of features detected by 
 61 
 
XCMS online (set under equal parameters) for both systems suggests dissimilar sensitivity 
for the vast majority of compounds. We presume the differences in the number of 
preliminary identification are likely due to databases used in each program. METLIN 
database within XCMS, includes 961,829 molecules (as of 2018) ranging from lipids, 
steroids, small peptides, carbohydrates, exogenous drugs/metabolites, central carbon 
metabolites and toxicants. The results from this comparison is in agreement with a previous 
report86 that there is only a partial overlap in the results obtained with different software 
programs of LC-MS metabolomic analysis. Even within the same software, the use of 
different parameters and thresholds strongly affects peak detection performance.105  
3.5. Conclusions  
 
This study evaluated reproducibility, mass accuracy, resolution, signal to noise 
ratio in a comparative analysis of small molecules in lipid-enriched extracts that used both 
a Q-TOF (Synapt) and LTQ-Orbitrap (Velos) instruments. Overall, both Synapt and 
Orbitrap mass spectrometers showed adequate mass accuracies. However, the accuracy 
was better using the Synapt for multiple lipid standards in both positive and negative ESI. 
The LTQ-Orbitrap had higher mass resolution from 200 to 700 m/z, while the Synapt had 
higher mass resolution from 700 to 1200 m/z values. Reproducibility associated with the 
metabolite peak intensities was better using the Synapt in both positive and negative ESI.  
Synapt data showed significantly higher signal to noise values (65% and 75% of the 
detected features on both instruments have relative S/N greater than 1 in positive and 
negative ESI respectively), which is an advantage in omics studies of biological matrices. 
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Differences in signal to noise ratios obtained on the two instruments were not statistically 
significant in the negative ESI data. XCMS was preferred as automated software for 
processing the metabolomics data while assigning more peak IDs in a shorter time. Taken 
together, our results suggest that, as used in this study, Q-TOF is better suited for 
untargeted metabolomics and lipidomics studies. 
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Chapter 4: Comparative Lipidomic Analysis of lipid droplets from C. elegans at 
Different Ages   
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Lipid droplets are cytoplasmic organelles that store neutral lipids for membrane 
synthesis and function as cellular energy reserves.39 The lipid droplets are composed 
primarily of triacylglycerols, surrounded by a phospholipid monolayer composed mainly 
of phosphatidylcholine and phosphatidylethanolamine. The significance of lipid droplets 
in regulation of various cellular processes, lipid homeostasis, transport, and metabolism is 
increasingly recognized, yet the unique lipid composition and properties of lipid droplets 
remains poorly understood.133 Here, an LC/MS method was employed to investigate the 
composition of purified Caenorhabditis elegans (C. elegans) lipid droplets to characterize 
their lipid profiles in an aging study. Comparison of the lipid droplet profiles of nematodes 
at Day 1 (D1), Day 4 (D4), and Day 7 (D7) of the adult stage showed alterations in the 
lipidome over different stages of adulthood. Untargeted LC/MS analysis resulted in 82 
metabolite features with significantly changed abundance in all the biological replicates in 
D1 compared to D4 samples, 95 metabolite features with statistically changed abundance 
in D1 compared to D7 samples and 16 metabolite features with statistically changed 
abundance in D4 compared to D7 samples. From the 65 potential identifications of 
triglycerides detected in both day 1 and day 7 samples, 90.7% increased in abundance with 
age. From the 59 potential identifications of triglycerides detected in both day 1 and day 4 
samples, 94.5% increased in abundance with age. From the 12 potential identifications of 
triglycerides in both day 4 and day 7 samples, 83.3% increased in abundance with age. 
Overall, this lipidomics survey provides further incentive to systematically study lipid 
droplets, so that a better understanding of aging related lipid dysfunction can be achieved.  
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4.1. Introduction 
Over the past decades, a large body of work has led to the identification of genes and 
proteins that affect longevity in different model organisms. Recently, it was discovered that 
lipids play vital roles in human physiological and pathological processes.134,135 However, 
the role of lipids in aging remains poorly understood.  The nematode Caenorhabditis 
elegans (C.elegans) is being used extensively as a model organism for understanding the 
molecular mechanisms of aging.136,137 The popularity of C. elegans as an aging model is 
largely due to its short life span (~ three weeks), and the ability to knock down genes that 
affect worm function and behavior. The nematode can easily be maintained under 
laboratory conditions and is used in high-throughput automated experiments.  
C. elegans store neutral lipids in cytosolic lipid droplets (LDs). Lipid droplets are fat-
storing organelles consisting of a hydrophobic core of triacylglycerol (TAG) and 
cholesterol ester surrounded by a phospholipid monolayer containing various proteins (see 
Chapter 2).8,138 Lipid droplets are involved in membrane synthesis and are energy 
reserves.8,39,139 In addition to energy storage and membrane synthesis, lipid droplets play 
important roles in the regulation of various cellular processes, including lipid transport 
and cellular metabolism.140,141 Prior work showed that lipid composition of this model 
organism may change during aging, since the pathways that influence aging also regulate 
lipid metabolism pathways.142,143 Previous aging related studies exhibited several 
differences in the composition of lipid droplets isolated from wild type C. elegans and 
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longer lived daf-2 mutants.144 Some studies describe an increase in the abundance of TAGs 
sequestered within LDs in the long lived daf-2 mutants.136,145  
 Comprehensive measurement of lipids is challenging due to their diverse structures. 
Liquid chromatography coupled to mass spectrometry (LC/MS) is the most broadly 
applicable technology in the field of metabolomics and lipidomics, which allows relative 
and/or absolute quantification.146 Use of LC/MS techniques give the possibility to separate 
and quantitate different classes of compounds according to their physicochemical 
properties. Due to their high sensitivity, selectivity, and mass accuracy, high resolution 
mass analyzers are often the method of choice for providing global metabolite analysis.147  
Data processing and compound identification is still the bottleneck in LC/MS based 
metabolomics.146 The data-processing pipeline usually proceeds through multiple stages 
(see Chapter 2). Computational tools and online databases have been developed for mass 
spectral lipid analysis including METLIN, MassBank, and LipidMaps.100,112 In a former 
study comparing multiple data processing software (the work described in Chapter 3), we 
indicated that XCMS allows for data processing tasks to be programmed and performed 
automatically. In addition, XCMS shows significant advantages over other data processing 
methods. These include the ease of peak integration and detection, automated statistical 
analysis, and multiple visualization tools of raw data for validation purposes.105,148  
Here we used an optimized mass spectrometry and data analysis method (see 
Chapter 3) to profile the composition of purified lipid droplets in adult C. elegans of 
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different ages. Our findings show that the dynamics of LD metabolome are influenced by 
C. elegans aging, in particular, that aging affect lipid storage in lipid droplets. 
4.2. Materials and Methods 
 
4.2.1. Reagents 
 
Buffers used for lipid droplet isolation were as follows: Buffer A is composed of 
20 mM tricine and 250 mM sucrose by dissolving 1.79 g of tricine in 400 ml of deionized 
(DI) water and 50 ml of 2.5 M sucrose in 500 ml of DI water. The pH was adjusted to 7.8 
with KOH. Buffer B is composed of 20 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), 100 mM KCl and 2 mM MgCl2 (pH 7.4) by 
dissolving 0.95 g of HEPES, 1.49 g of KCl and 0.038 g of MgCl2 in 180 ml of deionized 
water. The pH was adjusted to 7.4 with KOH and the volume was brought up to 200 ml. 
Collagenase 3 buffer used for worm homogenization included 100 mM Tris-HCl, and 1 
mM CaCl2, with or without Collagenase 3 enzyme (collagenase 3). The solvents used for 
extraction were HPLC grade chloroform and methanol from Fisher Scientific (Fairlawn, NJ). 
Butylated hydroxytoluene (BHT) was made by dissolving 100 mg of 2,6 Di-tert-butyl-
methyl phenol (Sigma Aldrich) in chloroform. M9 buffer (42 mM Na2HPO4, 22 mM 
KH2PO4, 86 mM NaCl, and 1 mM MgSO4.7H2O) was used for washing worms off the 
plate (200 µl for Day 1 to 400 µl for Day 4 and Day 7). Protease Inhibitor cocktail (AEBSF, 
aprotinin, bestatin, E-64, leupeptin and pepstatin A, Thermo Fisher, Waltham, MA) were 
added to all buffers in accordance with manufacturer’s instructions. Canola Oil (15 mg/ml) 
in chloroform (Sigma Aldrich) was used as the standard for lipid quantification. Vanillin 
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(Sigma Aldrich), o-phosphoric acid (85%), and sulfuric acid (95-98%, Sigma Aldrich) 
were used for lipid quantification.  
4.2.2. Lipid Droplet (LD) Isolation  
 
This part was performed by Joseph Renner Daniele and Gilbert Garcia, who were in 
Andrew Dillin’s laboratory, Department of Molecular and Cell Biology, University of 
California, Berkley. C. elegans cultures (~200,000 worms from 200 plates at 1000 worms 
per plate) were collected from day 1, day 4, and day 7 adult stage into a large beaker by 
washing them off plates with M9 + 0.1% Tween. Worms were transferred to 50 ml tubes 
and sedimented at 200 g at 4 °C for 5 minutes to reduce volume. The pellet was collected 
and transferred to 15 ml tube and washed once with 10 ml of M9 + 0.1% Tween and then 
with 10 ml of M9. Sedimented pellet was treated with collagenase buffer (at 1 mg/ml 
concentration) and the tube was incubated at 20 ºC with end over end agitation for 30 
minutes. Worms were sedimented at 2,000 g for 5 minutes and the collagenase buffer was 
aspirated. Worms were washed 5 times with M9 at room temperature and washed twice 
with cold Buffer. 
The pellet was moved on ice to a metal Dounce homogenizer with a glass pipette. The 
pellet was resuspended in Buffer A and protease inhibitor to a final volume of 7 ml of 
worms/buffer and was homogenized with 20 strokes (on ice). Worm lysate was transferred 
into 15 ml conical tubes on ice and the homogenizer was washed with ~3.5 ml Buffer A 
(with protease inhibitor) to collect all the lysate. The lysate (500 µl) was saved on ice and 
frozen with liquid nitrogen; the remaining 10 ml of lysate was spun at 1,500 g for 11 
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minutes at 4 ºC to pellet nuclei/debris. The nuclear pellet was resuspended in 1.5 ml of 
Buffer B (with protease inhibitor) and frozen in a tube with liquid N2. Homogenized C. 
elegans fraction was transferred into a 12 ml Ultra Centrifuge SW41 tube and Buffer B 
(with protease inhibitor) was carefully layered on top and the tube spun at 11,000 rpm 
(15,000 g) for 70 min at 4 ºC. LD fraction (white, cloudy) was collected from the top of 
the tube and was transferred via a glass pipet to a siliconized microcentrifuge tube. 
Collected fraction was spun at 18,000 g for 10 minutes and the bottom, aqueous layer was 
removed. Isolated lipid droplets were shipped to University of Minnesota (UMN) in 
chloroform on dry ice. Samples were stored at -80 ºC under nitrogen until LC/MS analysis. 
4.2.3. Metabolite (Lipid) Extraction 
 
Ice cold methanol and chloroform (1:1) were added to the collected lipid droplet 
samples and vortexed for 30 seconds at 4 ºC. Samples were shaken for 20 minutes with a tube 
shaker set to 1400 rpm and vortexed for additional 30 seconds. Sample tubes were 
centrifuged at 20,000 g for 10 minutes at 4 ºC. Polar phase was collected and stored at -80 
ºC. Protein interphase between the aqueous and organic phase was removed and 200 µL of 
nonpolar phase was collected by tilting tube 45 ºC and transferred to ice cold glass vials. 
Chloroform (2 ml) was added to each sample vial followed by an addition of 5 µl of 10 
mg/ml BHT/chloroform and stored at -80 ºC.  
  Ice cold methanol (1 ml) was added to the interphase protein fraction and spun at 
20,000 g for 10 minutes at 4 ºC. Methanol was then removed from protein pellet and the 
organic phase was dried under vacuum and was centrifuged at 30 ºC for 15 minutes. Pellets 
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were resuspended in 2x Laemmli buffer (200 µl for Day 1 to 400 µl for Day 4 and Day 7).  
Samples were pipetted up and down and stored at -80 ºC. 
4.2.4. Lipid Quantification   
 
A modified colorimetric method was used for quantitative analysis of total lipids. The 
sulfo-phospho-vanillin (SPV) assay149 possesses many advantages including small amount 
sample volume, less time and less labor, and more consistent color development. Canola 
oil used as a generic triglyceride standard was loaded into 96 well plate in a range of 0 mg 
to 3.6 mg of lipids in chloroform. Purified lipid droplet samples were added (10 µl) into 
empty wells, in triplicate. The solvent was evaporated under chemical fume hood and 100 
µl of sulfuric acid was added to all wells and incubated at 90 °C for 10 min. Vanillin/H2O 
(6.4 ml of 1mg/ml) mixture, 8 ml o-phosphoric acid, and 25.6 ml hot water was freshly 
made and used to make the final vanillin reagent. The plate was cooled on ice to room temp 
(~2 min) and 100 µl of vanillin-phosphoric acid reagent was added to all wells. After ~5 
min the color was developed and absorbance was measured at 540 nm on a UV 
spectrophotometer.150 Samples were normalized to the total lipid content (100 µg/ml) upon 
injection to the LC/MS. 
4.2.5 LC/MS Conditions 
 
Samples were resuspended in 200 ml 1:1 v/v methanol:chloroform to a final concentration 
of 50 μg/ml and were vortexed for 30 s to resuspend the pellet. A Waters Acquity UPLC coupled 
to a Waters Synapt G2 HDMS quadrupole orthogonal acceleration time of fight mass 
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spectrometer was used for UPLC/MS analysis. The reversed-phase column used was a Waters 
HSS T3 C18, 2.1 mm × 100 mm (1.7 μm diameter particles) operating at a temperature of 45 
°C. The following gradient separation was employed at a flow rate of 400 µL/min using a 
binary solvent manager system (Waters). Mobile phase A included Methanol:Water, 60:40 
v/v, with 10mM ammonium acetate, containing 0.1% formic acid. Mobile phase B was 
Methanol:Isopropanol 10:90 v/v with 10mM ammonium acetate, containing 0.1% formic acid. 
The gradient profile was: 40% B, 0 min to 5 min; 40% B to 100% B, 5 min to 13 min; 100% B, 
13 min to 16 min.  
The Waters Synapt instrument was tuned with the tuning solution containing sodium 
iodide in 50:50 2-propanol:water. Simultaneous low- and high-collision energy (CE) mass 
spectra were collected in centroid mode over the range m/z 50–1200 every 0.2 s during the 
chromatographic separation. Samples were analyzed in high-definition mode (HDMS) and 
the TOF analyzer was operated in the V resolution mode. MS parameters in positive 
electrospray ionization mode were as follows: capillary, 0.3 kV; sampling cone, 35.0 V; 
extraction cone, 5.0 V; desolvation gas flow, 800 L/h ; source temperature, 100 °C; desolvation 
temperature, 20 °C; cone gas flow, 20 L/h; trap CE, off (low CE collection), trap CE ramp 15–
65 V (high CE collection); lockspray configuration used the average of three m/z measurements 
(0.2 s scan, m/z 100–1200, every 10 s) of protonated leucine-enkephalin (m/z 556.2771) formed 
from infusion of a 5 μg/ ml solution. All MS parameters were identical in negative ionization 
mode except the following: capillary, 2.5 kV; sampling cone, 30.0 V; extraction cone, 4.0 V.  
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4.2.6. Data Processing 
 
For each age (D1, D4, D7), there were three biological replicates. Each one of three 
biological replicates were analyzed three times. Data collected on the Synapt G2 Q-TOF 
were processed by XCMS online software.105 Raw data acquired were converted to mzXml 
common data format using Proteowizard file converter (proteowizard.sourceforge.net) and 
the following parameters were used in this analysis: (i) Feature detection: centWave 
method, minimum peak width = 5 and maximum peak width = 20, S/N threshold = 6, 
mzdiff = 0.01, integration method = 1, prefilter peaks = 3, prefilter intensity = 100, noise 
filter = 0; (ii) Retention time correction: Obiwarp method, profStep = 1; (iii) Alignment: 
mzwid = 0.015, bw = 5, minfrac = 0.5, max = 100, minsamp = 1. Principle component 
analysis (PCA) was used for selecting the metabolite features that are significantly different 
among the sample groups (see Chapter 2). The three biological replicates of each age were 
combined and then all features, regardless of whether they were detected once, twice, or 
three times in the replicates, were used for comparison with other age groups. The data 
were processed for peak detection, retention time correction, chromatographic alignment, 
and identification through METLIN database. A workflow (See Chapter 2) was used to 
evaluate and confirm preliminary identification of features by XCMS.91  
Extracted ion chromatograms (XICs), were manually examined to select those 
features that have a true chromatographic peak profile, referred to as Checkpoint 1 in the 
workflow (see Chapter 2). Retention time correction was applied to the raw data to generate 
an extracted ion chromatogram for each technical replicate. Fragmentation patterns of 
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features with matches in the databases were evaluated to provide preliminary 
identifications, referred to as Checkpoint 2 (see Chapter 2). The top features with the 
highest significant difference (p-value > 0.05) and the greatest fold change (fold change > 
2) were selected from each LC/MS dataset. P-values were calculated in XCMS by 
performing a Welch’s t-test for unequal variances. Identifications were based on a 
METLIN search of the accurate masses. Multiple adducts were used for the database 
search. In silico fragmentation data were generated at collision energies of 10, 20, and 40 
eV. 
Cloud plots and Volcano plots were used in this study for visualization of 
metabolites that show a combination of fold change and statistical significance (p-value).151 
The three pairwise files that were generated by XCMS were imported into meta-XCMS 
and filtered by fold change (≥ 2) and p-value (≤ 0.05). Meta-XCMS is a software for 
performing second-order ("meta") analysis of untargeted metabolomics data from multiple 
sample groups. Performing second-order (meta-analysis), facilitates the integration and 
identification of shared patterns of metabolic variation across the results of multiple 
biologically relevant samples.113  
4.3. Results  
 
Ultra-high performance liquid chromatography (UPLC) coupled to acquisition of 
low- and high-collision energy mass spectra analysis was carried out to investigate the 
composition of enriched lipid droplet fractions from C. elegans. For this analysis, we 
compared the profiles of lipid droplets isolated from nematodes of different ages. For 
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investigating metabolite changes, we chose to compare lipid profiles of C. elegans at their 
reproductive stages of adulthood (D1 to D4) and middle-aged adults (D7) to describe 
changes of lipid droplet composition with aging. The link to a full list of identifications is 
provided in Appendix A.  
4.3.1. The Composition of Lipid Droplets isolated from C. elegans Differs with Age  
 
The goal of this experiment was to determine metabolite features whose abundance 
were significantly different between two ages (D1 versus D4, D1 versus D7, D4 versus 
D7). These are referred as D1D4, D1D7, and D4D7, respectively, in the rest of this chapter. 
Metabolite profiling from D1, D4, and D7 C. elegans lipid droplet fractions was performed 
by LC/MS. The XCMS online platform was used to visualize and interpret the data. A 
workflow was utilized to make preliminary identifications from each of the two-group 
comparisons (see Chapter 2).  
Comparison of D1 and D4 samples sets, using LC/MS in the negative ionization 
mode, resulted in 127 data features. Checking for statistical significance of each feature, 
25 hits had a p-value ≤ 0.05, 5 hits had a fold change ≥ 2 and 4 hits were selected that had 
both p-value ≤ 0.05 and fold change of ≥ 2. At a mass window of 5 ppm, none of these four 
compounds pass the XIC inspection in either samples D1, D4 or both (see Chapter 2). 
Based on the results, negative ionization mode was not used for the rest of the experiments.  
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Using LC/MS in the positive ionization mode enabled multiple comparisons. 
Tables 4.1, 4.2, and 4.3 show the number of mass features that are statistically different 
(fold change (≥ 2) and p-value (≤ 0.05)) in D1D4, D1D7, and D4D7 comparisons. 
  
Replicate 
1 
Replicate  
2 
Replicate  
3 
Raw Data 1078 993 1041 
P-value < 0.05 297 485 452 
Fold Change > 2 439 673 587 
P-val < 0.05 and FC > 2 254 453 397 
XIC checkpoint 73 423 389 
 
Table 4.6. Summary of hits resulting from the comparative analysis of lipid droplets isolated from C. elegans 
at Day 1 and Day 4 of adulthood. Data are from three independent biological replicates, each analyzed once. 
Lipid extractions included both polar and non-polar extractions (see Materials and Methods). ESI analysis 
was performed in positive (+) ionization mode.  
 
  
Replicate  
1 
Replicate  
2 
Replicate  
3 
Raw Data 1095 993 1091 
P-value < 0.05 311 485 534 
Fold Change > 2 471 673 703 
P-val < 0.05 and FC > 2 271 453 500 
XIC checkpoint 235 445 481 
 
Table 4.7. Summary of hits resulting from the comparative analysis of lipid droplets isolated from C. elegans 
at Day 1 and Day 7 of adulthood. Other conditions are as described in Table 4.1. 
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Replicate 
1 
 Replicate 
2 
 Replicate 
3 
Raw Data 1124 1087 1118 
P-value < 0.05 140 317 319 
Fold Change > 2 177 258 341 
P-val < 0.05 and FC >2 79 178 202 
XIC checkpoint 54 70 235 
 
Table 4.8. Summary of hits resulting from the comparative analysis of lipid droplets isolated from C. elegans 
at Day 7 and Day 7 of adulthood. Other conditions are as described in Table 4.1. 
 
Figures 4.1, 4.2, and 4.3 illustrate data supporting the identification of features that 
passed the XIC checkpoint in D1D4, D1D7, and D4D7 comparisons.  
Reproducibility of the mass spectral intensities of a given feature that appeared at 
least in one of the biological replicates was calculated after checkpoint 2. The values 
included in these comparisons varied widely. Coefficient of variations (CVs) for D1, D4 
and D7 had ranges of 3-156 % (average = 29 ± 18, n = 368), 1-116 % (average = 201 ± 15, 
n = 199), and 2 -79 % (average = 18 ± 14, n = 408) respectively. While it is usually 
recommended to remove individual features with CV > 30% when comparing technical 
replicates,152 we anticipated larger variations among these biological replicates, therefore, 
features with large CVs were not removed.  
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Figure 4.14. Preliminary identification of m/z 942.8615 in lipid droplet enriched fractions of Day 1 and Day 
4 samples. (A) Structure of 1-(9Z,12Z-octadecadienoyl)-2,3-dieicosanoyl-sn-glycerol, (B) Extracted ion 
chromatogram of Day 1 (black) and Day 4 (red) samples collected in positive ESI, (C) Matching in silico 
predicted MS spectra by METLIN. (TR = 10.23 min, p-value = 2.67 x 10-4). 
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Figure 4.15. Preliminary identification of m/z 922.7050 in lipid droplet enriched fractions of Day 1 and Day 
7 samples. (A) Structure of (1-(9Z,12Z-octadecadienoyl)-2,3-di-(5Z,8Z,11Z,14Z,17Z-eicosapentaenoyl)-sn-
glycerol), (B) Extracted ion chromatogram of Day 1 (black) and Day 7 (red) samples collected in positive 
ESI, (C) Matching in silico predicted MS spectra by METLIN. (TR = 14.55 min, p-value = 4.91 x 10-6). 
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Figure 4.16. Preliminary identification of m/z 596.5379 in lipid droplet enriched fractions of Day 4 and Day 
7 samples. (A) Structure of 1-octadecanoyl-2-hexadecanoyl-sn-glycerol, DG (18:0/16:0/0:0), (B) Extracted 
ion chromatogram of Day 4 (black) and Day 7 (red) samples collected in positive ESI, (C) Matching in silico 
predicted MS spectra by METLIN. (TR = 7.86 min, p-value = 2.99 x 10-3). 
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Visualization of comparisons of features that passed the XIC checkpoint (Tables 
4.1, 4.2, and 4.3) is key to identify metabolites of potential biochemical interest. 113 The 
results of using three visualization tools are shown in Figures 4.4, 4.5, and 4.6.  
Common and distinct features are visualized by traditional Venn diagram (Figures 
4.4A, 4.5A, and 4.6A). The numbers of shared metabolite features that are significantly 
altered in each of the three biological replicates are displayed at the center of each Venn 
diagram.  
The interactive cloud plot of XCMS online was used to facilitate the comparison 
and characterization of metabolite features in this untargeted analysis (Figures 4.4B, 4.5B, 
and 4.6B). The interactive cloud plots have improved interpretation capabilities over the 
Volcano plots, which use only p-value and fold-change in intensity to identify features of 
interest (Figures 4.4C, 4.5C, and 4.6C). To use of interactive cloud plots made possible 
improve the power of comparisons because it provides information about m/z, retention 
time, p-value, fold change, and potential identification.  
Using the interactive cloud plots, among the 82 features common in the comparison 
of D1 versus D4 (Figure 4.4A), 72 had METLIN identifications. Similarly, for the 
comparison of D1 versus D7 (Figure 4.5A), 77 out of the 95 common features had 
METLIN identifications. Lastly, the comparison of D4 versus D7 samples (Figure 4.6A), 
14 out of 16 common features had METLIN identifications. These identifications are 
documented in Appendix A.  
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Figure 4.17. Comparative visualization of Day 1 versus Day 4 data. (A) Venn diagram illustrate the overlap 
of shared changed preliminary identifications between the three biological replicates. (B) Cloud plots 
indicating the metabolite features whose level varies significantly across the two age groups. Each metabolite 
feature is represented by a bubble. Statistical significance (p-value) is represented by the bubble’s color 
intensity. The size of the bubble denotes feature fold change. Features surrounded by a black line have 
database hits in METLIN, (C) Volcano plots displaying the metabolites that are statistically and biologically 
significant (p-value below a 5% significance level based on a t-test and an average fold change larger than 
2). Metabolites with a relatively low fold-change between the two groups appear near the center and 
metabolites that have significant p-values are found in the upper-right or upper-left regions.153  
 82 
 
 
Figure 4.18. Comparative visualization of Day 1 versus Day 7 data. Other details are as described in Figure 
4.4. 
 
 83 
 
 
Figure 4.19. Comparative visualization of Day 4 versus Day 7 data. Other details are as described in Figure 
4.4. 
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There were 13 features that were detected in each of the biological replicates of D1, 
D4, and D7 samples. The comparison of the average abundance of these features among 
D1, D4 and D7 was used to build a heat map (Figure 4.7). The heat map analysis displays 
the relative increase or decrease of each one of these features, identified by its m/z value, 
relative to D1. All features show statistically significant (p-value < 0.05, fold change 
(FC) ≥ 2) changes in abundance. The heat map shows four hits (m/z 845.77, 911.79, 943.81, 
and 955.19) whose abundance is different between D1, D4 and D7. The respective 
preliminary identifications in METLIN are: 1-hexadecanoyl-2,3-di-(9Z,12Z-
heptadecadienoyl)-sn-glycerol, 1-(9Z,12Z-heptadecadienoyl)-2-(9Z,12Z,15Z-
octadecatrienoyl)-3-(11Z-eicosenoyl)-sn-glycerol, 1-(9Z,12Z-heptadecadienoyl)-2,3-di-
(11Z-eicosenoyl)-sn-glycerol, and 1-(9Z-octadecenoyl)-2,3-di-(11Z,14Z-eicosadienoyl)-
sn-glycerol.  
  
 85 
 
 
Figure 4.20. Heat map of relative abundance of features commonly detected in D1, D4, and D7 samples. 
Columns represent pairwise comparisons and rows refer to m/z values. Shades of red represent elevation of 
a metabolite and shades of green represent a decrease of a metabolite relative to the median metabolite levels 
in the early age group (see scale).  
4.3.2. Most Significant Lipids Changed in Lipid Droplets with Aging  
 
The comparative analysis of three independent lipid droplet preparations for each 
D1, D4, and D7 nematodes pointed to multiple compounds that showed differences in 
abundance (Figures 4.4, 4.5, and 4.6). Lipids categorized as triglycerides (TG) were among 
the top compounds to significantly increase in abundance in D7 vs D1 lipid droplets (fold 
change ranging from 3.22 to 44.7). From the 65 potential identifications of triglycerides 
detected in both day 1 and day 7 samples, 90.7% increased in abundance with age. From 
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the 59 potential identifications of triglycerides detected in both day 1 and day 4 samples, 
94.5% increased in abundance with age. From the 12 potential identifications of 
triglycerides in both day 4 and day 7 samples, 83.3% increased in abundance with age.  
Other lipid species to show an increase in abundance in D7 samples relative to D1 
age group were phospholipids. As an example, compound with m/z 806.5699 preliminary 
identified as 1-hexadecanoyl-2-(4E,7E,10E,13E,16E,19E-docosahexaenoyl)-sn-glycero-
3-phosphocholine increased in D7 samples by a fold change of 30.6 compared to D1 (p-
value = 0.007). The lipid with m/z 663.4966, preliminary identified as 1-dodecanoyl-2-
heneicosanoyl-glycero-3-phosphate, increased by 31.5-fold in D7 samples relative to D1 
age group (p-value = 0.0001).  
Lipids categorized as phosphatidylglycerols (PG) were among compounds to 
significantly (p-value < 0.05, fold change (FC) > 2) decrease in D7 vs D1 lipid droplets. 
Examples include: the lipid m/z 740.5824, had a 16 fold decrease in abundance in D7 
samples and was identified as 1-octadecyl-2-pentadecanoyl-glycero-3-phospho-(1'-sn-
glycerol). Another lipid (m/z 745.5374), that significantly decreased by 10.7 fold in D7 
samples compared to D1 was preliminary identified as 1-(1Z-octadecenyl)-2-(9Z,12Z-
heptadecadienoyl)-glycero-3-phospho-(1'-sn-glycerol). Compound with m/z 881.7444 
preliminary identified as 1-eicosyl-2-docosanoyl-glycero-3-phospho-(1'-sn-glycerol), 
decreased by 16.2 fold in D7 samples compared to D1.  
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4.4. Discussion 
The goal of this study was to investigate the age-related changes of the composition 
of lipid droplets purified from nematodes at D1, D4, and D7 of adulthood. LC/MS analysis 
followed by XCMS analysis of data lead to selection of features that display differences in 
abundance between ages. Older nematodes displayed an increase in the abundance of TGs 
and a decrease in the abundance of PGs in lipid droplets (See the link to preliminary 
identifications in Appendix).  
This is in agreement with previous reports that several long-lived C. elegans strains 
have enlarged LDs with increased PC and LysoPC contents compared to wild type.154 This 
is also consistent with prior work that found an aging-related decline in the C. 
elegans homolog of phospholipase D3, an ER membrane protein that hydrolyzes PC into 
choline and phosphatidic acid.155  
Other reports showed several phospholipids including PCs and PEs were abundant 
during the larval stage and early adulthood (Day 1) and lowered during the remainder of 
adult lifespan.156 In the same study, other PLs such as PG and SM species presented an 
opposite pattern; they were less abundant during early adult stages and accumulated at later 
stages of life. Results for changes in PL abundance during aging are provocative and there 
is no clear correlation in the literature. This is not surprising since PL synthesis is derived 
from a series of processes that results in complex lipid compositions with different head 
groups and multiple acyl chains.  
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Furthermore, performing pairwise comparisons, we observed an increase in the 
abundance of TGs in lipid droplets with aging (90.7% from day 1 to day 7, 94.5% from 
day 1 to day 4, 83.3% from day 4 to day 7). Triacylglycerol is the major storage form of 
energy in animals and are crucial for normal cellular functioning such as maintenance of 
membrane composition.6  The regulation of triacylglycerol plays a critical role in disorders 
such as aging, obesity, and diabetes.42,157 Aging was previously shown to be associated 
with increased rates of FA uptake, and rates of FA uptake correlated with rates of TG 
synthesis. Studies on the effects of aging on FA metabolism are few and have focused on 
the basal state. However, in general, these studies have indicated that cellular FA disposal 
is altered with aging.158  
It is assumed that TG accumulation with aging could be attributed to an increase in 
TG synthesis, a decrease in TG utilization, or both.158 However, the metabolic factors 
responsible for the accumulation of TG with aging have not been determined.  
4.5. Conclusions 
 
The LC/MS based analysis and data analysis workflow employed here resulted in 
193 preliminary identifications of enriched lipid droplets isolated from C. elegans. These 
represent compounds with changes in abundance as a function of the nematode’s age. We 
observed that the lipid composition of lipid droplets is affected and altered by aging. These 
identifications require further exploration, which ultimately may provide a framework to 
elucidate the role of lipid droplets in the mechanisms of aging and age-related diseases.  
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Chapter 5: Lipidomic Analysis of Enriched Lipid Droplets from Young and 
Geriatric Mice Reveals Distinct Signatures of Aging  
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Aging is a progressive process that includes the loss or decline of tissue and organ 
function over time.122 Changes in lipid storage and dysfunction in lipid droplet (LD) 
processes are commonly associated with several diseases including aging.7,10,159 
Characterizing LDs composition is important for investigating their role in altered lipid 
storage disorders. Ultra-high pressure liquid chromatography coupled to mass 
spectrometry99 are used in this study to determine age associated changes in the lipid 
composition of lipid droplets isolated from mouse liver tissue. Mass spectrometry data 
reveals total 416 features that are significantly changed in young and old mice in positive 
electrospray ionization (ESI) mode (p-value ≤ 0.05 and fold change of ≥ 2). This number 
is 12 for negative ESI. Lipid droplets purified from livers of old mice are highly enriched 
in triacylglycerols. In addition, such lipid droplets have lower phospholipid (mainly 
phosphatidylcholine and phosphatidylethanolamine) content compared to young liver 
tissue. These preliminary identifications suggest future areas of focus on the analysis of 
lipid droplets lipidomes and investigation of LD roles in aging related disorders.  
5.1. Introduction 
Aging is defined as a decline in biological functions, and the progression of aging is 
well known to result in altering lipid metabolism.160 Lipids are widely involved in a variety 
of biological functions and exhibit structural and chemical variety with diverse head groups 
and fatty acid chains.161 The dysregulation of lipid metabolism due to aging impacts human 
health significantly.29,122  
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Within cells, lipids are stored in specialized organelles called lipid droplets 
(LDs).133,141,162 Lipid droplets are intracellular structures, which serve as energy 
reservoirs. Lipid droplets are shielded by a phospholipid monolayer, mostly 
phosphatidylcholine with lesser amounts of phosphatidylethanolamine, 
phosphatidylinositol, lyso-phosphatidylcholine, and lyso-phosphatidylethanolamine.41 The 
monolayer surrounds a hydrophobic oil core which mainly comprises triacylglycerols 
(TAG) and sterol esters.163-165 Lipid droplets participate in many cellular processes in 
different organisms.159,162 Abnormal lipid accumulation in lipid droplets in the liver has 
been reported in many metabolic diseases, including the metabolic syndrome and 
obesity.159  
Ultra performance liquid chromatography coupled to mass spectrometry (UPLC/MS)  
based lipidomic approaches, are becoming specialized tools for better understanding of 
LDs and lipid metabolism at systems biology levels.44,45 These “omics” approaches allow 
dissection of subcellular organelle lipidomes and identification of LD roles in lipid 
metabolism. In this work, we profiled the liver lipid droplet compositions of young (35 
weeks), and geriatric (115 weeks) mice. LC/MS comparison resulted in more than 500 
features for both the old and young LDs, of which 343 features changed significantly 
(p-value < 0.05, Fold Change > 2) during aging in positive ESI mode. Out of these, 199 
compounds had assigned IDs and 145 compounds remained unidentified. In negative 
ESI mode, 12 features changed significantly from young to old mice. Out of these, 8 
compounds were identified using online libraries and 4 remained unidentified.  We 
found that compounds preliminary identified as triglycerides were more abundant in 
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LDs in old mice; however, compounds identified as phospholipids showed lower 
abundance in aged mice. 
5.2. Materials and Methods 
 
5.2.1. Reagents 
 
Sucrose and ethaminetetraacetic acid (EDTA) were obtained from Sigma Aldrich 
(St. Louis, MO). Tris base was obtained from Thermo Fisher (Waltham, MA). Water was 
purified with a Millipore Synergy UV system (18.2 mΩ/cm, Bedford MA). Liver 
homogenization buffer (Buffer H) consisted of 250 mM sucrose, 10 mM Tris, pH 7.0. 
Buffer A consisted of 500 mM Sucrose, 2 mM EDTA, and 1.22 g Tris-base in 500 mL 
water, pH 7.8. Sucrose gradient step solutions were mixed with Millipore water to a final 
concentration of 1X Buffer A. Pierce Protease Inhibitor Mini Tablets (AEBSF, aprotinin, 
bestatin, E-64, leupeptin and pepstatin A, Thermo Fisher, Waltham MA) were added to all 
buffers in accordance with manufacturer’s instructions (simply dissolve 1 tablet in 10 mL 
of buffer or lysate). The solvents used for extraction were HPLC grade chloroform and 
methanol from Fisher Scientific (Fairlawn, NJ). Canola Oil (15 mg/ml) in chloroform 
(Sigma Aldrich, 100ml) was used as the standard for lipid quantification. Vanillin (Sigma 
Aldrich), O-phosphoric acid (VWR, 85%), and Sulfuric Acid (95-98%, Sigma Aldrich, 100 
ml) were used for lipid quantification. 
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5.2.2 Lipid Droplet Isolation from Mouse Liver Tissue 
 
This part was done by Katherine A. Muratore at University of Minnesota. Lipid 
droplets were prepared from the liver tissues of C57BL6 female mice.166 Mice in the adult 
group were ~35 weeks and mice in the geriatric group were ~115 weeks. All isolation steps 
were performed at 4 °C. Mice were euthanized by intraperintal injection of pentorbital 
(mg/g) and the liver was excised. The liver was weighed and minced in a petri dish using 
a flat razorblade into small (1 mm) pieces and resuspended in 3 ml of Buffer H. The liver 
was transferred into a nitrogen cavitation chamber and charged to 200 psi. After 15 minutes 
on ice, the cell lysate was released from the nitrogen cavitation chamber into a 50 ml 
conical tube and centrifuged at 1000 g for 10 minutes. The post nuclear supernatant was 
loaded onto a sucrose step gradient (4 mL 35% Sucrose Buffer A, 4 mL 25% Sucrose 
Buffer A) and centrifuged at 36,000 rpm in a Beckman SW 41 rotor for 4 hours. The lipid 
droplet fraction appeared as white film at the top of the tube, which was removed with a 
Pasteur pipette.165 All mice were housed in a designated clean facility and treated in 
accordance with protocols approved by the University of Minnesota Insitutional Animal 
Care and Use Committee. 
5.2.3. Metabolite (Lipid) Extraction 
 
A previously published protocol was used to extract the lipids from purified lipid 
droplet fractions.108 Briefly, 3.75 ml of ice cold chloroform : methanol 1:2 v/v was added 
to 1 ml of the collected fraction and vortexed for 2 min. Sample was treated with 1.25 ml 
of chloroform and vortexed for 1 min. Subsequently, 1.25 ml of water was added to the 
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sample and vortexed for 1 min. Sample was centrifuged in glass tubes at 13,000 g for 10 
min to pellet any non-extracted materials. The upper phase containing salts and other water 
soluble metabolites were removed and protein phase was pierced and discarded. The 
organic phase (lower phase) was collected and transferred to a new sterile siliconized 
Eppendorf tube and evaporated overnight at room temperature under vacuum to remove 
extraction solvents. Tubes were filled with nitrogen to remove any air and stored dry at -
80 °C prior to analysis. 
5.2.4. Lipid Quantification 
 
A modified colorimetric method was used for quantitative analysis of total lipids 
(See Materials and Methods in Chapter 3).149,150 Lipid standards (canola oil) were loaded 
into 96 well plate in a range of 0 mg to 3.6 mg of lipids. Samples were added (10 µl), in 
triplicate, to each well. The solvent was evaporated in the hood and 100 µl of sulfuric acid 
was added to each well and incubated at 90 °C for 10 min. Vanillin (1 mg/ml), 8 ml o-
phosphoric acid, and 25.6 ml hot water were used to make the final vanillin reagent. The 
plate was cooled on ice to room temp (~2 min) and 100 µl of vanillin reagent was added to 
each well. After ~5 min the color was developed and absorbance was measured at 540 nm.  
5.2.5. UPLC/MS Conditions 
 
Samples were resuspended in 200 ml 1:1 methanol:chloroform to a final 
concentration of 50 μg/ml and were vortexed for 30 s. A Waters Acquity UPLC coupled 
to a Waters Synapt G2 HDMS quadrupole orthogonal acceleration time of flight mass 
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spectrometer was used for UPLC/MSe analysis. The reversed-phase column used was a 
Waters HSS T3 C18, 2.1 mm × 100 mm column (1.7 μm diameter particles) operating at a 
temperature of 45 °C. The following linear gradient separations were employed at a flow 
rate of 400 µL/min using a binary mobile phase system where A: Methanol: Water, 60:40 
v/v, 5 mM ammonium formate, containing 0.1% formic acid and B: Methanol:Isopropanol 
10:90 v/v, 5 mM ammonium acetate, containing 0.1% formic acid. The gradient profile 
was: 40% B, 0 min to 10 min; 40% B to 100% B, 10 min to 15 min; 40% B, 15 min to 20 
min. The Waters Synapt G2 was calibrated for mass accuracy with 2 µg/µl sodium iodide 
solution in 50/50 2-propanol/Water. Simultaneous low- and high-collision energy (CE) 
mass spectra were collected in centroid mode over the range m/z 50–1200 every 0.2 s 
during the chromatographic separation. Samples were analyzed in high-definition MSe 
mode (HDMS) and the TOF analyzer was operated in the V resolution mode. 
MSe  parameters in positive electrospray ionization mode were as follows: capillary, 0.3 
kV; sampling cone, 35.0 V; extraction cone, 5.0 V; desolvation gas flow, 800 L/h; source 
temperature, 100 °C; desolvation temperature, 20 °C; cone gas flow, 20 L/h; trap CE, off 
(low CE collection), trap CE ramp 15–65 V (high CE collection); lockspray configuration 
consisted of infusion of a 5 µg/mL solution of leucine-enkephalin and acquisition of one 
mass spectrum (0.2 s scan, m/z 100-1200) every 10 s. Three lockspray m/z measurements 
of protonated leucine-enkephalin were averaged and used to apply corrections to measured 
m/z values during the course of the analysis. All MSe parameters were identical in negative 
ionization mode except the following: capillary, 2.5 kV; sampling cone, 30.0 V; extraction 
cone, 4.0 V. 
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5.2.6. Data Treatment 
 
Samples were categorized into two groups of young (n=4, biological replicates) and 
old (n=4, biological replicates). Each sample was analyzed separately using the the Synapt 
G2 Q-TOF instrument. Collected data were processed by XCMS online software 
(xcmsonline.scripps.edu). Raw data acquired were converted to .mzXml common data 
format using Proteowizard file converter (proteowizard.sourceforge.net) and the following 
parameters used in this analysis: (i) Feature detection: centWave method, min. and max. 
Peak width = 2 and 25, S/N threshold = 10, mzdiff = 0.01, integration method = 2, prefilter 
peaks = 3, prefilter intensity = 500, Noise filter = 0; (ii) Retention time correction: 
Obiwarp method, profStep = 1; (iii) Alignment: mzwid = 0.015, bw = 2, minfrac = 0.5, 
max = 1000, minsamp = 1. The data were processed for peak detection, retention time 
correction, chromatographic alignment, statistical analysis, and identification through 
METLIN database with 5 ppm tolerance. The identifications include possible adducts, 
fragments and isotopes. A workflow that has been previously developed in our lab was 
used to make preliminary identification of features by XCMS (See Chapter 2).91 Extracted 
ion chromatograms (XICs), were manually examined to confirm that identified features 
have a true chromatographic peak profile, referred to as Checkpoint 1 in the workflow (see 
Chapter 2). Fragmentation patterns of each feature from low- and high- collision energy 
mass spectra were examined to provide preliminary identifications of features, referred to 
as Checkpoint 2 (see Chapter 2). 
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Each biological replicate was run three times and reproducibility of the peak 
intensities for each biological replicate was calculated after all checkpoints. This value was 
between 4 % and 107 % CV, (Average ± Standard deviation, 24 ± 16, N= 219) in young 
mouse liver in positive ion mode, and between 61 % and 106 % CV in negative ion mode 
(Average ± Standard deviation, 95 ± 26, N= 12). This value is between 1.4 % and 85 % in 
LDs isolated from old mouse liver (Average ± Standard deviation, 19 ± 9, N= 219) in 
positive ion mode, and between 11 % and 98 % in negative ion mode (Average ± Standard 
deviation, 79 ± 17, N= 12).  
5.3. Results  
 
We used UPLC/MS analysis to investigate the lipid composition of lipid droplets 
(LDs) in mouse liver tissue.167,168 A chemometric approach known as principle component 
analysis (PCA) was used for processing the UPLC/MS data to expedite the classification 
of potential features into one of two comparative biological fractions (young and old). We 
found that triglycerides (TAG) showed higher abundance (defined by fold change) in lipid 
droplets isolated from old mouse compared to young. Also, compounds identified as PC 
and PE showed lower abundance in lipid droplets isolated from old mouse compared to 
young. The link to a full list of identifications is provided in Appendix B. 
 
5.3.1. Preliminary Identifications from Mouse Liver 
 
Using positive ESI, in total we found 1346 features that were detected at least once 
in both young and old groups, but had different signal intensities between the age groups. 
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Comparative analysis of the resulting total ion chromatograms was performed using XCMS 
software tool. Cloud plots of MS analysis revealed 343 hits (counting isotopes of each 
feature as one hit) with a p-value ≤ 0.05 and fold change of ≥ 2 (Figure 5.1.A). Complete 
lists of these features that change in abundance (p-value < 0.05 and FC > 2) are summarized 
in Table B.1 of Appendix B. Searching against the METLIN database resulted in 119 
features with matching MS/MS spectra. The interactive volcano plot in Figure 5.1.B shows 
the relationship between statistical significance (often scaled logarithmically) and 
biological relevance (often presented in terms of fold change). Two regions of interest in 
the volcano plot include those points that are found towards the top of the plot that are far 
to either the left- or the right-hand side. These represent values that display large magnitude 
fold changes as well as high statistical significance (p-value). Yet, volcano plots do not 
provide information about feature intensity and retention time that are often important for 
the interpretation of metabolomics results. Results from volcano and cloud plots are 
complimentary (Figure 5.1 A and B). 
In negative ESI mode, 12 features differed in signal intensities between the young 
and old age groups. A representation of the cloud plot and the volcano plot results is shown 
in Figure 5.2.  
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Figure 5.21. Mass spectrometry results of enriched lipid droplet fractions in young and old mouse liver 
samples in positive ESI. (A) Cloud plots indicating features whose level varies significantly in young and 
old lipid droplets. Each metabolite feature is represented by a bubble. Statistical significance (p-value) is 
represented by the bubble’s color intensity. Features with low p-values are brighter compared to features with 
high p-values. The size of the bubble denotes feature fold change. Features surrounded by a black line have 
database hits in METLIN, (B) Volcano plots displaying features that are statistically and biologically 
significant (p-value below a 5% significance level based on Welch t-test with unequal variances and an 
average fold change larger than 2). Metabolites with a relatively low fold-change between the two groups 
appear near the center and metabolites that have significant p-values are found in the upper-right or upper-
left.  
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Figure 5.22. Mass spectrometry results of enriched lipid droplet fractions in young and old mouse liver 
samples in negative ESI. See Figure 5.1 for details.  
 
5.3.2. Triglycerides Increase in Aged Liver Lipid Droplets  
 
An increase in the abundance of triglycerides (TG) was observed in the aged liver 
lipid droplets. Three examples include: a protonated peak of a compound with m/z 
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929.7541, tentatively identified as 1,2-di-(9Z,12Z,15Z-octadecatrienoyl)-3-eicosanoyl-sn-
glycerol, increased in abundance in the old liver lipid droplets by a fold change of 3.6 (p-
value= 0.04). Figure 5.3 illustrates data supporting the identification of such compound.  
The structure (A), the aligned extracted ion chromatograms (B), and the mass spectrum at 
10.45 min (C) of this compound are shown in this figure. Sodium adduct of a 
compound with m/z 753.4884, tentatively identified as 1-(7Z,10Z,13Z,16Z,19Z-
docosapentaenoyl)-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-glycerol, increased 
in abundance in the old mice by a fold change of 2.9 (p-value= 0.0001). Protonated mass 
of a compound with m/z 941.6986, tentatively identified as 1-hexadecanoyl-2,3-di-
(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycerol, increased in abundance in the old liver 
lipid droplets by a fold change of 2.9 (p-value= 0.02). See Appendix B.  
No TGs were identified in negative ESI mode.  Lists of 12 features that change in 
abundance (p-value < 0.05 and FC > 2) in negative ESI are summarized in Appendix Table 
B.2.  
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Figure 5.23. Preliminary Identification of m/z 929.7541. A) Structure of 1-hexadecanoyl-2-(9Z-
octadecenoyl)-3-(7Z,10Z,13Z,16Z,19Z docosapentaenoyl)-sn-glycerol, found in lipid droplet enriched 
fractions; B) Extracted ion chromatogram for m/z 929.7541; C) Mass spectrum at TR: 10.45 min; (p-value: 
0.04, fold change: 3.6).  
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5.3.3. Phospholipids Decrease in Aged Liver Lipid Droplets  
 
There is a reduction in the abundance of phosphatidylcholines (PCs), 
phosphatidylethanolamines (PEs), phosphatidic acids (PAs), and phosphatidylinositols 
(PIs) in lipid droplets from liver of 115 weeks old mice compared to young (35 weeks) 
samples. Examples include: Compounds with m/z 832.5854 and 806.5697 preliminary 
identified as 1-(9Z-octadecenoyl)-2-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-sn-
glycero-3-phosphocholine, and 1-hexadecanoyl-2-(3Z,6Z,9Z,12Z,15Z,18-
docosahexaenoyl)-sn-glycero-3-phosphocholine, significantly decreased in abundance in 
lipid droplets of old mice liver by fold changes of 4 and 3.8, respectively (p-value < 0.01). 
PEs with m/z 766.5384 and 772.5848 preliminary identified as 1-palmitoyl-2-
docosapentaenoyl-sn-glycero-3-phosphoethanolamine, and 2-octadecanoyl-3-(5Z,8Z-
eicosadienoyl)-sn-glycero-1-phosphoethanolamine, considerably decreased in the old liver 
lipid droplets by fold changes of 3.8 and 3.2, respectively (p-value < 0.03). The sodium 
adduct of a feature tentatively identified as 1-docosanoyl-2-eicosanoyl-glycero-3-
phosphate (PA(22:0/20:0)) with m/z 811.6196 decreased in lipid droplets of old mice liver 
by a fold change of 3.2. Another feature identified as 1-(1Z-hexadecenyl)-2-tridecanoyl-
glycero-3-phospho-(1'-myo-inositol) with m/z 753.4884 significantly decreased in old 
groups compared to young lipid droplet samples by a fold change of 2.7.  These examples 
were selected because of their highest significant difference (Wilcoxon rank test) and the 
greatest fold change (See Appendix B).  
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 Top lipids that significantly decreased (p-value < 0.01) in lipid droplets of old 
mouse liver in negative ESI, were also tentatively identified as phospholipids. [M-H]- of a 
feature tentatively identified as 1-tridecanoyl-2-(4Z,7Z,10Z,13Z,16Z,19Z-
docosahexaenoyl)-glycero-3-phosphocholine with m/z 764.5230 decreased in abundance 
in lipid droplets of old mice liver by a fold change of 2.3. Another lipid tentatively 
identified as 1-hexadecyl-2-(9Z-tetradecenoyl)-glycero-3-phosphate, with m/z 605.4539 
decreased in lipid droplets of old mice liver by a fold change of 2. Another compound 
tentatively identified as 1-(5Z,8Z-eicosadienoyl)-2-octadecanoyl-sn-glycero-3-
phosphoethanolamine with m/z 772.5848 decreased in abundance in lipid droplets of old 
mice liver by a fold change of 3.2. See Appendix B. 
5.4. Discussion 
 
In this study, we used UPLC/MS to investigate the lipidomic profile of lipid 
droplets in the liver of young and geriatric mice. Although the biogenesis of lipid droplets 
is relatively well documented, little is known about changes in their composition and 
structure as a function of aging. Currently there are no studies assessing age-related 
changes in the lipid composition of lipid droplets.   
The variety of the different phospholipids in lipid droplet monolayer protecting the 
neutral lipids from the hydrophilic environment of the cell suggests that they play important 
tasks in regulating the structure and function of this cellular organelle.169-171 In mammalian 
cells and yeast, phosphatidylcholine (PC) with 60% of the total lipid content is the most 
prominent phospholipid in the lipid droplet outer layer.139,172 Phosphatidylethanolamine 
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(PE) and phosphatidylinositol (PI), ranging up to 24% and 8% are the second and third 
most abundant lipids in the outer layer.172,173 Other phospholipids including PS and the 
lyso-forms of PC and PE are present in minor amounts.  
PCs are crucial to stabilize growing LDs and they play key roles in maintaining the 
stability of LDs in cells.12 In addition, the surface lipid monolayer could also be involved 
in the differential recruitment of lipid droplet proteins. This phospholipid class in general 
has been shown to decrease with age in mouse mitochondrial fractions of brain and liver 
tissues.174 The same decreasing trend was observed in the results obtained on lipid droplets 
in our work. We observed that lipids preliminary identified as PCs are decreased in the 
lipid droplets isolated from old mouse liver compared to young. However, reports on age 
related changes on the composition of phospholipids have made contradictory 
observations. PCs were previously shown to either increase or decrease in aged mice, 
compared to young mice in targeted metabolomic analysis of serum metabolites.170 A 
decrease in the abundances of phosphatidic acid (PA) was also observed with age in our 
work. As an example, compound preliminary identified as 1-docosanoyl-2-eicosanoyl-
glycero-3-phosphate (22:0/20:0) decreased in abundance in old samples compared to 
young (p-value = 0.002, fold change = 4.3). In previous studies, PAs have not been found 
in considerable amount in lipid droplets lipid profiles.7,175  
TGs are involved in normal cellular functioning such as energy storage and 
maintenance of membrane composition.176 General accumulation of TGs is found in aging, 
obesity and type 2 diabetes.177,178 TG content has previously shown to increase in 
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mitochondria-rich tissues including heart, liver, and skeletal muscle in rat models of 
aging.179 Similar trend was observed in the abundances of TGs in lipid droplets isolated 
from old mouse liver. It has been proposed that a metabolic shift is in the conversion of 
diacylglycerol to triglycerides is caused by aging.176  
 Further biological insight could be gained through parallel lipidomics studies of 
aging related diseases in different model organisms. Overall, results obtained here are in 
agreement with our prior lipidomics findings in C. elegans described in Chapter 4; in which 
lipid droplets are enriched in TGs during aging and the surrounding phospholipid 
monolayer have lower levels of PC and PE.  
5.5. Conclusion 
 
 Comparative lipidomic analyses of mouse lipid droplets were conducted in this 
study. We have demonstrated that enriched lipid droplet fractions have characteristic 
lipidomic profiles specific to their age. Preliminary identifications of the lipid components 
in lipid droplets isolated from mouse liver suggest an increased TG content and decreased 
PC and PE content during normal aging. These data suggest that changes in LD 
compositions impact lipid metabolism. 
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Chapter 6: Conclusions and Future Work  
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6.1. Conclusions 
 
 At the onset of this work, there were no reports of a systematic characterization 
and comparison of lipids found in lipid droplets from different aging populations. The work 
described in this thesis applied LC/MS strategies to investigate the compositions of lipid 
droplets and determine age associated changes in lipid profiles. Untargeted characterization 
of lipids in lipid droplets was performed by LC/MS on a Q-TOF mass spectrometer of C. 
elegans at different ages, and liver of young and geriatric mice. This resulted in 
preliminarily identifications of compounds that were significantly changed between aging 
groups. These preliminary results are important in understanding age associated changes 
of lipid droplet compositions. 
The diversity of lipids makes it highly unlikely to have universal analysis 
procedures for this class of compounds.180,181 A wide range of mass spectrometry 
instruments is currently being used for lipid analysis. However, none of these platforms 
have been comprehensively compared for their analytical capabilities in analyzing lipids. 
The work described in Chapter 3 provides a comparison of the performances of high 
resolution Q-TOF (Synapt G2) and Orbitrap (Velos) instruments for lipidomic analysis. 
The main analytical parameters that influence detection and identification of lipids specific 
to a biological sample were explored. Overall, the mass accuracy was better using the 
Synapt for multiple lipid standards in both positive and negative ESI. The LTQ-Orbitrap 
had higher mass resolution from 200 to 700 m/z, while the Synapt had higher mass 
resolution from 700 to 1200 m/z values. Reproducibility associated with the metabolite 
 109 
 
peak intensities was better using the Synapt in both positive and negative ESI. Synapt data 
showed significantly higher signal to noise values (65% and 75% of the detected features 
on both instruments have relative S/N greater than 1 in positive and negative ESI 
respectively), which is an advantage in omics studies of biological matrices. Differences 
in signal to noise ratios obtained on the two instruments were not statistically significant 
in the negative ESI data. XCMS was preferred as automated software for processing the 
metabolomics data while assigning more peak IDs in a shorter time. Taken together, our 
results suggested that, as used in this study, Q-TOF is better suited for untargeted 
metabolomics and lipidomics studies. 
Advances in the mass spectrometry field have enabled the large scale 
characterization of lipids in a variety of biological samples .19 Yet, integration and 
visualization of metabolomics data is a formidable task that requires advanced 
computational framework.182 Four different algorithms were used to analyze the mass 
spectrometry data from the Synapt G2 and Orbitrap Velos instruments and their ease of use 
and robustness were compared. XCMS software offered a powerful solution ranging from 
basic data structures to sophisticated algorithms for data analysis. Additionally, a rigorous 
data analysis workflow was used to both select features that had extracted ion 
chromatograms with acceptable chromatographic peak profiles and to ensure that the 
product ions from high collision energy mass spectra possessed matching XIC with its 
parent ion.91 
The optimized mass spectrometry platform and data analysis workflow described 
in Chapter 3 were used to compare the composition of lipid droplets of C. elegans at Day 
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1, Day 4, and Day 7 of age. This nematode has been successfully used as a model of aging, 
but knowledge of its LD lipid and protein compositions are still rather limited.144 Our 
findings suggest that lipid droplets have increased TG content and decreased phospholipid 
(PC, PG) content with age. Metabolomic studies of C. elegans have contributed 
significantly to the understanding of the biology of aging of other organisms.142,183 Aging 
in C. elegans share many similar characteristics with aging in humans including general 
decline in cellular function, and reducing the capability to respond to internal and external 
stress. However, it is still unknown how aging affects lipid droplet composition and fat 
storage in different model organisms. Our lipidomic analysis revealed distinct lipid 
compositions specific to each age group. Further validation of these results will open new 
avenues to understand how lipid droplets impinge on lifespan regulation in C. elegans and 
possibly humans.  
Our workflow was also used to compare the lipid droplet compositions of liver in 
young and geriatric mice. The lipid composition of lipid droplets had previously not been 
determined in this context by any non-targeted methods including LC/MS. Preliminary 
identifications were assigned to features enriched or unique to lipid droplets in young and 
old mouse models (Chapter 4). Comparison of lipid profiles enriched from mouse liver 
resulted in 416 features that are significantly altered from young to old lipid droplets in 
positive ESI. This number was 12 in negative ESI. Many of the preliminary identifications 
made, such as PE(16:0/0:0) and sphinganine, have previously been associated with aging 
indicating that the preliminary identifications made may be of high relevance to age related 
diseases.184 In the future, identifications will be validated and investigated for their specific 
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role in lipid droplet biology and aging.  
 The findings described in this thesis suggest age associated changes in the lipidomic 
profiles of lipid droplets in two different model organisms. These preliminary 
identifications may lead to additional follow-up experiments to further increase our 
understanding of how lipid droplet composition changes and contributes to aging.  
6.2. Future Work  
 
The reconstruction of lipid metabolism pathways requires novel strategies for the 
mapping of lipid data at the molecular species levels instead of at lipid class/subclass 
levels.185 This reconstitution also requires the integration of comprehensive lipidomic data 
with genetic, transcriptional, and enzyme data to perform metabolic pathway and flux 
analyses.37 Defining lipid identities is a challenging task because of the large structural 
diversity of lipid classes and lipid species. This task requires a combination of novel and 
existing bioinformatics resources. Additional developments of those reported in this thesis 
could provide new insights into the biology of lipids. These developments include: 
validating the preliminary identifications using standards and making additional database 
entries (Section 6.2.1.), isolating high purity subcellular organelles (Section 6.2.2.), and 
improving lipid analysis using ion mobility mass spectrometry (Section 6.2.3.).  
  
6.2.1. Improve and Validate Preliminary Identifications 
 
 
As described throughout this thesis, LC/MS was used to make preliminary 
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identifications of metabolites from enriched lipid droplets in two different model 
organisms. Using the workflow91, of the 82 features detected in all D1D4 comparisons 12 
compounds were not identified with online database searches (the work described in 
Chapter 4). Of the 95 features detected in all D1D7 comparisons 17 compounds were not 
identified. Of the 16 features detected in all D4D4 comparisons 2 compounds were not 
identified with online database searches. Of the 343 features detected in lipid droplet 
fractions of old and young mouse liver in positive ESI, 181 were not identified with online 
database searches (the work described in Chapter 5). This number is 3 out of 12 for the 
data collected in negative ESI. Searching in a molecular structure database is clearly 
limited to those compounds present in the database.186 Thus, there is a need to enrich the 
mass spectrometry databases to improve the number of identifications and decrease the 
experimental time needed to validate preliminary identifications. Various databases have 
been developed to aid in assigning structures to spectral peaks observed in metabolomics 
experiments. Several recent reviews have discussed the general capabilities of various MS-
based databases and software tools.187 Additional database entries produced by the LC/MS 
community could also lower the risk of false positive identifications and increase the 
confidence in the results.188  
The work described in Chapters 4 and 5 made several preliminary identifications 
of features enriched in lipid droplets of different age groups. Validation of preliminary 
identifications is always needed to confirm their identification and is relatively 
straightforward if high quality commercial standards are available. Future validation will 
require acquisition of high quality commercially available standards that are analyzed by 
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LC/MS using the exact same methodology applied to lipid samples. This includes 
comparison of extracted ion chromatograms, low energy mass spectra, and high energy 
mass spectra. The standard will need to be run neat/in solution, spiked in biological matrix, 
and spiked and extracted in biological matrix for the full structural elucidation.143 
Information would also need to be collected on targeted precursor ion and neutral loss 
scans, as well as MS/MS spectra to help validate the data. If the preliminary identification 
is correct, the mass spectra of the biological feature and the commercial standard should 
be very similar. In summary, having lipid standards will help strengthen tentative 
identifications.  
6.2.2. Improving Purification of Subcellular Organelle Enrichment 
 
 
An isolation procedure which enriches a specific organelle and minimizes 
contaminations by membranes from other organelles is beneficial to reliable profiling of 
lipids and assignation of biological function. It is also known that employing inadequate 
purification methods when performing lipidomics analyses may lead to inaccurate 
selection of tentative biomarkers.51,53  
To improve and adapt the method discussed in Chapters 4 and 5 to other subcellular 
organelles in different model organisms, new methodologies could be utilized to increase 
the purity and yield of subcellular organelle isolation. Alternative methods such as 
immunoisolation techniques could be developed to overcome the problems with other 
techniques such as density gradient centrifugation. A major advantage of antibody-based 
separation techniques is the specificity that antibodies bring to the separation, enabling an 
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organelle type to be selectively isolated from the complex biological system.189 
Generally, a molecular target unique to an organelle type that is usually found on 
the surface of such organelles would be identified and an antibody that binds specifically 
to that target would be selected. Organelles will be captured with magnetic beads coated 
with such antibodies against the desired targets by using a magnet (Figure 6.1).190 
. 
 
 
Figure 6.24. Diagram of an immunoisolation experiment using magnetic beads. The sample contains both 
the desired organelle with the molecular target of the antibody and other organelles. Magnetic beads with 
conjugated antibody against the molecular target are added to the sample. Organelles bound by antibodies 
conjugated to the magnetic beads are retrieved using a small magnet at the side of the tube and the unbound 
organelles are washed away. 
 
6.2.3. Improving Lipid Analysis by Ion Mobility Mass Spectrometry 
 
 
Detection of cis/trans isomerism is an important aspect in current biological and 
medical lipid research.132 The change from cis to trans geometry is evoked by peroxidation 
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and involvement in electrophilic free radical reactions. Alterations in the geometry of lipids 
severely impacts their membrane functions and signaling properties and are thought to play 
a major role in aging and health impairments.191 
Due to the complexity of the lipidome and the significant amount of isobaric and 
isomeric overlap, the detailed examination of lipids is challenging. High throughput 
structural analysis of lipids has been recently demonstrated through the use of rapid gas 
phase separation on the basis of the ion mobility (IM) combined with mass spectrometry 
(IM/MS).132,192 The Synapt G2 instrument described in Chapter 2 has T-Wave ion mobility 
to significantly enhance the peak capacity, specificity, and sensitivity of biomolecule 
analysis.  
The most straightforward method of measuring the ion mobility is the drift time 
method in which the arrival time of a distribution of ions is recorded under the influence 
of a weak electric field.71 Drift time ion mobility methods have been successfully used to 
investigate the mobility-mass (drift time and m/z) correlation profiles of signals obtained 
from phosphatidyl-choline (PC), -ethanolamine (PE), -serine (PS), -inositol (PI), -glycerol 
(PG), phosphatidic acid (PA), and sphingomyelin (SM) lipid containing standards.193 
IM/MS is also able to distinguish fatty acid (FA) isomers with cis- and trans-orientations 
for the monounsaturated FAs. Therefore, further advances in lipidomic analysis of the lipid 
droplets and other organelles should consider the use of IM/MS. 
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6.2.4. Concluding Remarks 
This chapter points to future approaches to advance the work described in this 
thesis, which contributes to our fundamental understanding of lipid droplets and how their 
lipidomic profile changes in aging.  
In general, the findings in this thesis add significantly to the field of lipidomic 
analysis and opens up opportunities for new studies to determine the role of aging in lipid 
droplet biology.  
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Appendix A 
Supplementary Material to Chapter 4 
Comparative Lipidomic Analysis of lipid droplets from C. elegans  at Different Age. 
 
ID Fold p-value Change m/z Rt Name 
2 263.24 0.0029 UP 922.7871 10.5 TG(18:3/18:3/20:1) 
4 240.82 0.0032 UP 923.791 10.5 TG(18:0/18:2/19:0) 
88 110.59 0.0399 UP 948.8024 10.56 TG(18:2/20:3/20:3) 
223 98.26 0.0254 UP 888.9749 10.73 TG(17:1/18:1/18:1) 
102 96.17 0.0046 UP 927.8213 10.73 TG(18:3/18:3/20:1) 
47 92.19 0.0089 UP 920.771 10.34 TG(17:0/17:1/18:0) 
32 88.59 0.0036 UP 943.8519 11.01 TG(17:0/20:2/20:2) 
71 86.08 0.0035 UP 904.834 10.99 TG(16:1/16:1/22:0) 
287 84.39 0.0066 UP 925.8055 10.59 TG(18:3/18:3/20:2) 
49 83.55 0.0106 UP 942.756 10.17 TG(17:2/20:1/20:1) 
493 82.78 0.0246 UP 944.8647 11.15 TG(17:1/20:1/20:1) 
123 81.28 0.0485 UP 946.7866 10.42 TG(18:3/20:3/20:3) 
443 78.78 0.0145 UP 943.7589 10.17 TG(17:0/20:2/20:2) 
24 62.94 0.0289 UP 926.8174 10.72 TG(18:2/18:3/20:0) 
82 59.11 0.0074 UP 952.8334 10.79 TG(18:2/20:2/20:2) 
166 53.61 0.0113 UP 944.7704 10.27 TG(18:2/20:4/20:4) 
33 52.96 0.0033 UP 928.835 10.89 TG(18:1/18:3/20:0) 
143 51.26 0.0119 UP 954.848 10.91 TG(18:3/20:1/20:1) 
363 37.28 0.0057 UP 927.742 10.49 TG(18:3/18:3/20:1) 
55 32.77 0.0468 UP 918.8411 10.94 TG(18:3/18:3/20:3) 
105 31.73 0.0365 UP 889.8065 10.73 TG(16:1/17:0/20:1) 
158 30.81 0.0304 UP 968.7704 10.24 TG(20:4/20:4/20:4) 
61 30.76 0.0216 UP 910.7875 10.53 TG(17:2/18:3/20:1) 
283 29.02 0.0276 UP 889.9777 10.73 TG(16:1/17:0/20:1) 
63 28.45 0.0065 UP 866.7243 10.05 TG(12:0/18:1/22:6) 
22 26.98 0.0428 UP 960.8962 11.38 TG(18:2/20:0/20:0) 
372 26.85 0.0092 UP 928.7447 10.49 TG(18:1/18:3/20:0) 
67 25.42 0.0291 UP 905.8374 10.98 TG(17:1/18:3/19:0) 
95 22.67 0.0109 UP 942.8489 11 TG(17:2/20:1/20:1) 
119 22.14 0.0363 UP 888.8036 10.74 TG(17:1/18:1/18:1) 
56 21.72 0.0010 UP 890.8097 10.73 TG(16:1/17:0/20:1) 
135 21.38 0.0369 UP 887.7909 10.59 TG(17:2/18:2/18:2) 
58 21.10 0.0088 UP 906.8407 10.98 TG(16:1/17:0/21:0) 
172 20.36 0.0210 UP 918.7551 10.19 TG(18:3/18:3/20:3) 
484 18.10 0.0071 UP 888.7942 10.58 TG(17:2/18:0/18:1) 
6 17.72 0.0018 UP 880.7398 10.18 TG(16:1/17:2/20:4) 
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280 16.99 0.0214 UP 948.713 10.17 TG(18:2/20:3/20:3) 
43 16.02 0.0194 UP 914.7233 9.92 TG(18:3/18:3/20:5) 
399 15.61 0.0090 UP 858.7554 10.36 TG(15:0/16:0/20:4) 
252 13.44 0.0144 UP 854.7231 10.14 TG(17:2/17:2/17:2) 
131 12.56 0.0408 UP 933.786 10.87 TG(18:0/18:2/20:0) 
10 11.87 0.0103 UP 940.7392 10 TG(18:2/20:5/20:5) 
319 11.84 0.0218 UP 980.8641 11.11 TG(20:0/20:3/20:3) 
200 10.88 0.0034 UP 663.4964 7.74 
1-dodecanoyl-2-
heneicosanoyl-
glycero-3-phosphate 
78 9.89 0.0084 UP 860.7618 10.36 TG(13:0/18:3/20:0) 
434 9.35 0.0215 UP 892.8344 11.02 TG(17:1/18:0/18:0) 
45 9.04 0.0070 UP 830.7238 10.13 TG(12:0/15:0/22:4 
110 8.69 0.0114 UP 792.7085 10.11 TG(16:1/14:0/16:1) 
69 8.24 0.0000 UP 920.864 11.23 TG(18:3/18:3/20:2) 
322 7.99 0.0022 UP 966.754 10.09 TG(20:3/20:5/20:5) 
17 7.63 0.0050 UP 900.8032 10.65 TG(16:0/18:0/20:4) 
100 6.74 0.0002 UP 988.9273 11.53 TG(20:0/20:1/20:1) 
186 6.71 0.0414 UP 857.7417 10.27 TG(17:0/17:2/17:2) 
246 6.50 0.0098 UP 851.781 10.56 TG(14:0/14:0/22:0) 
176 6.32 0.0098 UP 888.7084 9.86 TG(17:1/18:1/18:1) 
207 6.14 0.0134 UP 940.8329 10.88 TG(18:2/20:5/20:5) 
170 5.80 0.0078 UP 894.8407 11.02 TG(18:3/18:3/20:3) 
487 5.73 0.0330 UP 921.7744 10.34 TG(17:0/18:3/20:0) 
44 5.45 0.0027 DOWN 868.7396 10.22 TG(16:0/16:1/20:5) 
220 4.62 0.0168 DOWN 796.6345 9.97 
N-(tricosanoyl)-
hexadecasphing-4-
enine-1-
phosphocholine 
31 4.54 0.0121 DOWN 840.7078 9.96 TG(18:3/14:0/18:3) 
37 4.38 0.0204 UP 805.7113 10.09 TG(14:0/14:0/19:1) 
209 4.29 0.0011 DOWN 855.7267 10.13 TG(16:0/16:0/18:1) 
249 4.21 0.0252 UP 962.723 9.81 TG(20:5/20:5/20:5) 
241 3.89 0.0040 DOWN 841.725 10.58 TG(16:0/16:1/17:0) 
495 3.62 0.0160 DOWN 839.7094 10.48 TG(13:0/18:1/18:1) 
272 2.43 0.0096 DOWN 834.2399 8.86 
N-(tetracosanoyl)-
sphinganine-1-
phosphocholine 
415 2.37 0.0015 DOWN 813.6942 10.35 TG(15:0/15:0/17:1) 
274 159.73 0.0422 UP 949.8058 10.56 NA 
168 123.91 0.0018 UP 951.8207 10.68 NA 
254 93.59 0.0269 UP 902.9913 10.81 NA 
149 85.14 0.0240 UP 945.7744 10.27 NA 
1 80.72 0.0045 UP 929.8376 10.89 NA 
60 71.78 0.0139 UP 955.8523 10.91 NA 
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144 49.10 0.0459 UP 895.7591 10.32 NA 
234 47.76 0.0082 UP 950.8091 10.56 NA 
76 45.97 0.0092 UP 911.7906 10.53 NA 
80 37.05 0.0357 UP 917.7424 10.13 NA 
351 34.61 0.0442 UP 909.7752 10.43 NA 
21 22.06 0.0047 UP 902.809 10.65 NA 
16 20.73 0.0017 UP 901.8063 10.65 NA 
425 19.60 0.0089 UP 947.7094 10.17 NA 
367 18.03 0.0124 UP 925.7254 10.34 NA 
364 16.76 0.0202 UP 893.7422 10.1 NA 
479 15.85 0.0140 UP 949.7249 10.26 NA 
222 15.74 0.0048 UP 591.5699 11.29 NA 
121 14.98 0.0186 UP 967.7578 10.09 NA 
9 13.86 0.0158 UP 941.7425 10 NA 
489 9.06 0.0068 UP 945.8688 11.14 NA 
229 7.73 0.0118 UP 861.7757 10.6 NA 
297 7.21 0.0093 UP 931.7584 10.22 NA 
451 5.20 0.0166 UP 197.0819 9.97 NA 
127 4.22 0.0149 UP 907.845 10.99 NA 
463 4.12 0.0445 DOWN 793.7121 10.07 NA 
500 3.83 0.0001 UP 685.2045 8.1 NA 
 
Table A.9. Meta analysis of Day 1 and Day 7 samples. A list of corresponding m/z and 
retention time values along with potential matches to the METLIN database for the shared 
dysregulated metabolic features that are significantly altered in all of the technical 
replicates. NA: Not Assigned, PC: Phophatidylcholine, PE: Phophatidylethanolamine, 
TG: Triglyceride, DG: Diacylglycerol, SM: Sphingomyelin, CE: Cholesteryl ester, PA: 
Phophatidic acid, PS: Phophatidylserine, PI: Phosphatidylinositol. 
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 ID Fold p-value Change m/z Rt Name 
317 97.3 0.0057 UP 922.787 10.5 TG(18:3/18:3/20:1) 
312 86.4 0.0064 UP 923.791 10.5 TG(18:0/18:2/19:0) 
294 44.7 0.0095 UP 920.7706 10.34 TG(18:3/18:3/20:2) 
133 42.4 0.0054 UP 926.817 10.73 TG(18:2/18:3/20:0) 
5 40 0.0026 UP 916.8342 10.96 TG(17:0/18:3/20:0) 
95 38.6 0.008 UP 928.8339 10.89 TG(18:1/18:3/20:0) 
238 38.6 0.008 UP 928.8243 10.73 TG(18:1/18:3/20:0) 
430 34.2 0.0107 UP 948.8026 10.56 TG(18:2/20:3/20:3) 
125 33.1 0.0277 UP 942.8486 11.01 TG(17:2/20:1/20:1) 
121 30.3 0.0007 UP 850.7783 10.56 TG(16:0/16:0/18:1) 
43 28.5 0.0126 UP 942.7556 10.17 TG(17:2/20:1/20:1) 
209 28.1 0.0284 UP 954.8475 10.92 TG(18:3/20:1/20:1) 
54 26.8 0.0148 UP 943.7585 10.17 TG(17:0/20:2/20:2) 
355 23.3 0.0008 UP 888.9745 10.74 TG(17:1/18:1/18:1) 
76 23.3 0.00086 UP 888.8033 10.75 TG(17:2/18:0/18:1) 
69 22.5 0.0475 UP 887.7907 10.59 TG(17:2/18:2/18:2) 
32 19.7 0.0174 UP 859.7587 10.36 TG(16:1/17:2/18:0) 
161 19.4 0.0029 UP 927.8208 10.73 TG(18:3/18:3/20:1) 
275 19.4 0.0029 UP 927.741 10.5 TG(18:3/18:3/20:1) 
232 16.7 0.082 UP 910.7871 10.53 TG(17:2/18:3/20:1) 
399 16.5 0.0156 UP 918.842 10.96 TG(18:3/18:3/20:3) 
10 16.1 0.0472 UP 886.7875 10.59 TG(17:2/18:1/18:1) 
20 15 0.0031 UP 877.8062 10.78 TG(17:2/17:2/18:0) 
416 12.6 0.0314 UP 904.8339 10.99 TG(16:1/16:1/22:0) 
200 12.5 0.0021 UP 849.7749 10.56 TG(16:0/17:1/17:1) 
332 12.4 0.0157 UP 908.7718 10.43 TG(17:2/18:3/20:2) 
27 12 0.0399 UP 933.8683 11.19 TG(18:0/18:2/20:0) 
213 12 0.0399 UP 932.8647 11.19 TG(18:0/18:2/20:0) 
51 11.4 0.0074 UP 860.7626 10.4 TG(13:0/18:3/20:0) 
93 11.3 0.0184 DOWN 663.4958 7.74 
1-dodecanoyl-2-
heneicosanoyl-glycero-3-
phosphate 
217 10.9 0.0132 UP 892.8333 11.02 TG(17:1/18:0/18:0) 
82 9.9 0.0137 DOWN 834.7471 10.33 
N-(tetracosanoyl)-
sphinganine-1-
phosphocholine 
109 9.2 0.0123 UP 899.79 10.52 TG(17:2/17:2/20:3) 
250 9.2 0.0132 UP 899.7091 10.35 TG(17:2/17:2/20:3) 
211 8.7 0.0045 UP 844.7394 10.23 TG(16:0/17:2/17:2) 
123 8.4 0.0221 UP 960.896 11.39 TG(18:2/20:0/20:0) 
181 8.1 0.0044 UP 854.723 10.14 TG(17:2/17:2/17:2) 
4 7.4 0.024 UP 920.8555 11.13 TG(18:0/18:1/19:0) 
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87 7.3 0.0154 UP 940.7387 10 TG(18:2/20:5/20:5) 
282 6.9 0.0129 UP 921.7741 10.34 TG(17:0/18:3/20:0) 
122 6.7 0.0061 DOWN 795.7274 10.27 
N-(tricosanoyl)-
hexadecasphing-4-enine-1-
phosphocholine 
163 6.7 0.0061 DOWN 795.6317 9.97 
N-(tricosanoyl)-
hexadecasphing-4-enine-1-
phosphocholine 
11 6.3 0.0153 UP 889.8064 10.75 TG(16:1/17:0/20:1) 
49 6.3 0.0153 UP 891.8216 10.92 TG(16:1/17:0/20:1) 
428 6.3 0.0153 UP 890.8142 10.84 TG(16:1/17:0/20:1) 
129 5.9 0.0098 UP 806.7241 10.24 TG(13:0/17:1(9Z)/17:1(9Z)) 
319 5.3 0.0118 UP 937.8185 11.19 TG(18:0/18:2/20:0) 
144 5.3 0.0396 UP 840.7072 9.96 TG(18:3/14:0/18:3) 
182 5.2 0.0033 UP 769.6311 9.81 TG(12:0/12:0/20:2(11Z,14Z)) 
33 5.2 0.0272 UP 906.8492 11.16 TG(16:1/17:0/21:0) 
21 4.8 0.0117 UP 766.6917 10.01 TG(13:0/13:0/18:1) 
151 4.7 0.0165 UP 752.6768 9.84 TG(12:0/12:0/19:1(9Z)) 
306 4.7 0.0143 UP 797.6625 10.08 TG(16:1/14:0/16:1) 
120 4.5 0.0057 UP 878.8165 10.87 TG(17:0/17:1/18:0) 
141 4.2 0.0036 UP 794.7245 10.27 TG(16:0/14:0/16:1) 
91 2.5 0.0015 DOWN 855.7269 10.13 TG(16:0/16:0/18:1) 
260 2.3 0.0282 UP 823.7575 10.43 beta-hydroarchaetidylglyerol 
102 2.3 0.0073 UP 822.7537 10.42 TG(16:0/16:0/16:1) 
373 2.1 0.0106 DOWN 841.7233 10.59 TG(16:0/16:1/17:0) 
45 49 0.0059 UP 929.8373 10.89 NA 
67 15.6 0.0077 UP 883.7586 10.3 NA 
68 17.6 0.0007 UP 861.7748 10.61 NA 
99 19.6 0.207 UP 944.7623 10.22 NA 
105 15 0.0299 UP 846.7554 10.39 NA 
166 8.3 0.0213 UP 941.742 10.01 NA 
169 3.6 0.0073 UP 197.0817 9.97 NA 
185 13.8 0.0208 UP 947.7903 10.42 NA 
190 6.5 0.0015 UP 907.8436 10.99 NA 
216 26.6 0.0165 UP 930.8399 10.86 NA 
237 5.1 0.0057 UP 894.8401 11.02 NA 
259 11.2 0.0155 UP 915.7264 9.92 NA 
265 10.9 0.0095 UP 884.763 10.35 NA 
307 39.2 0.0363 UP 902.991 10.81 NA 
327 16.4 0.0055 UP 909.7749 10.43 NA 
331 5.5 0.0124 UP 765.6798 9.86 NA 
345 56.9 0.0885 UP 949.8055 10.56 NA 
347 18.4 0.095 UP 896.7635 10.31 NA 
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350 6.1 0.0108 UP 781.7113 10.1 NA 
384 3.2 0.0068 UP 864.7942 10.73 NA 
389 4.2 0.0288 UP 798.666 10.07 NA 
 
Table A.10. Meta analysis of Day 1 and Day 4 samples. A list of corresponding m/z and retention time values 
along with potential matches to the METLIN database for the shared dysregulated metabolic features that are 
significantly altered in all of the technical replicates. 
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ID Fold p-value Change m/z Rt Name 
53 9.4 0.0242 UP 944.7704 10.27 TG(16:1/20:5/22:4) 
131 7 0.047 UP 931.7581 10.22 TG(17:2/20:4/20:4) 
5 3.1 0.0146 UP 942.756 10.17 TG(18:3/20:4/20:4) 
13 3 0.1365 UP 955.8519 10.91 TG(17:1/19:0/22:3) 
50 3 0.027 UP 950.8091 10.56 TG(18:2/20:1/20:4) 
65 2.8 0.0096 UP 952.8326 10.79 TG(18:1/20:2/20:3) 
19 2.7 0.0291 DOWN 967.7574 10.09 PI(d20:0/26:0) 
51 2.5 0.0088 UP 911.791 10.53 TG(17:0/18:2/20:4) 
75 2.5 0.0088 UP 910.7879 10.53 TG(17:0/18:3/20:3) 
136 2.3 0.018 DOWN 767.6953 10.01 TG(13:0/13:0/18:1(9Z)) 
14 2.1 0.0202 UP 954.8477 10.91 TG(16:0/20:4/22:1) 
87 2.1 0.0018 UP 966.7546 10.09 TG(20:4/20:4/20:5) 
143 2 0.0146 UP 945.7741 10.27 TG(20:2/18:3/20:2) 
140 4.6 0.0404 UP 591.5689 11.29 NA 
77 3 0.0019 UP 953.836 10.79 NA 
71 2.1 0.0016 DOWN 1148.326 7.45 NA 
 
Table A.3. Meta analysis of Day 4 and Day 7 samples. A list of corresponding m/z and retention time 
values along with potential matches to the METLIN database for the shared dysregulated metabolic 
features that are significantly altered in all of the technical replicates. 
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Appendix B  
Supplementary Material to Chapter 5  
Lipidomic Analysis of Enriched Lipid Droplets from Young and Geriatric Mice Reveals 
Distinct Signatures of Aging  
 
ID Fold p-value Change m/z Rt Name 
5 44.07 0.0000 UP 850.6753 9.52 TG(16:1/14:0/18:1) 
3 37.31 0.0000 UP 849.6723 9.52 PS(O-18:0/22:1(11Z)) 
11 30.79 0.0001 UP 555.4562 10.29 Demethylspheroidene 
30 20.48 0.0005 UP 812.7000 10.29 TG(16:0/14:0/16:1) 
25 20.23 0.0004 UP 351.3052 11.10 PA(20:0/22:0) 
6 17.31 0.0000 UP 791.6700 11.10 PC(16:0/22:5) 
8 13.32 0.0001 UP 809.6800 9.52 
TG(12:0/17:0/20:3(8Z,11Z,14
Z)) 
47 11.71 0.0016 UP 811.6963 10.29 TG(16:0/14:0/16:1(9Z)) 
19 11.55 0.0002 UP 792.6736 11.10 TG(16:0/14:0/16:1(9Z)) 
109 11.25 0.0070 UP 931.7710 10.79 TG(18:2/18:3/20:3) 
15 9.73 0.0001 UP 501.0962 1.25 
2-(Diphenylphosphorothioyl)-
3-methyl-5,6-
diphenylphosphinine 
113 9.72 0.0072 DOWN 682.6494 11.52 18:1 Campesteryl ester 
100 9.12 0.0064 UP 992.9237 11.14 TG(18:3/20:2/20:2) 
16 8.27 0.0002 UP 828.6941 9.53 PC(22:6/18:2) 
92 7.82 0.0056 DOWN 311.2556 7.94 
1-[1,1-
Bis(pentyloxy)ethoxy]pentane 
110 7.77 0.0072 DOWN 758.7304 7.06 PC(16:0/18:3(6Z,9Z,12Z)) 
87 7.67 0.0051 DOWN 383.3678 11.53 PC (17:0-17:0) 
281 7.66 0.0260 DOWN 640.6031 11.14 Cholesteryl palmitelaidate 
28 7.60 0.0005 UP 827.6914 9.53 
TG(12:0/17:0/20:3(8Z,11Z,14
Z)) 
357 7.01 0.0380 DOWN 760.7466 7.45 PE(18:1(11Z)/18:1(9Z)) 
86 6.64 0.0049 DOWN 384.3709 11.52 PC(20:4/18:1) 
359 6.20 0.0383 DOWN 782.5694 6.81 PC(18:2/22:5) 
366 5.91 0.0403 UP 892.7403 10.12 TG(17:1/18:2/20:0) 
111 5.79 0.0072 DOWN 369.3521 11.65 
(5Z,7E)-9,10-seco-5,7,10(19)-
cholestatriene 
363 5.76 0.0393 UP 177.1650 11.98 
1,2-Dihydro-1,1,6-
trimethylnaphthalene 
68 5.65 0.0031 DOWN 675.6048 11.65 Cholesteryl stearate 
267 5.34 0.0237 UP 845.0954 10.28 TG(16:1/17:1/17:2) 
346 5.21 0.0364 DOWN 641.6061 11.14 Cer(d18:1/23:0) 
268 4.99 0.0242 UP 1080.9680 12.33 TG(17:1/17:1/17:1) 
234 4.75 0.0195 DOWN 813.6845 8.49 SM(d18:2/24:0) 
303 4.64 0.0288 UP 517.3864 4.56 TG(16:1/18:3/20:5) 
233 4.57 0.0193 DOWN 849.1276 10.62 PS(O-18:0/22:1(11Z)) 
217 4.43 0.0172 DOWN 847.1120 10.45 PC(18:1/20:5) 
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130 4.42 0.0092 DOWN 833.5888 7.13 PA(22:1(11Z)/22:2(13Z,16Z)) 
283 4.41 0.0261 DOWN 845.9101 10.28 PC(18:3/22:4) 
361 4.36 0.0388 DOWN 856.7398 10.24 TG(14:0/15:0/15:0) 
254 4.30 0.0222 DOWN 848.1136 10.45 PS(20:0/20:1(11Z)) 
127 4.27 0.0088 DOWN 807.5732 6.78 PC(20:4/18:1) 
285 4.16 0.0266 DOWN 844.9082 10.28 PC(20:4/16:0) 
331 4.05 0.0340 DOWN 780.5536 6.72 PC(16:0/22:4) 
152 4.04 0.0106 DOWN 831.5730 6.74 PC(20:4/20:4) 
194 4.03 0.0145 DOWN 670.6488 11.66 18:0 Cholesteryl ester 
150 4.01 0.0105 DOWN 832.5854 7.13 PC(20:3(8Z,11Z,14Z)/16:0) 
161 3.98 0.0113 DOWN 830.5695 6.74 PC(22:6/18:2) 
91 3.86 0.0055 UP 202.0339 1.39 
[6-(Methanesulfonyl)pyridin-
3-yl]boronic acid 
222 3.81 0.0175 UP 844.7403 10.28 TG(16:0/17:2/17:2) 
76 3.81 0.0037 UP 470.3106 5.03 TG(16:0/14:0/16:1) 
409 3.80 0.0483 DOWN 756.5545 6.61 PC(15:1(9Z)/20:1(11Z)) 
173 3.79 0.0121 DOWN 806.5697 6.79 PC(18:1/22:6) 
210 3.79 0.0167 UP 882.7550 10.30 TG(17:2/18:2/18:2) 
314 3.79 0.0304 DOWN 766.5384 7.00 PC(22:6/18:1) 
408 3.75 0.0482 DOWN 894.7466 10.11 PC(22:6/18:2) 
232 3.70 0.0193 DOWN 812.6159 7.90 PC(18:1/20:4) 
274 3.69 0.0251 DOWN 767.5418 7.00 PE(20:2(11Z,14Z)/16:0) 
242 3.68 0.0206 DOWN 847.9253 10.45 PC(16:0/22:6) 
145 3.67 0.0102 UP 595.4699 8.07 DG(16:0/16:0/0:0) 
247 3.67 0.0213 DOWN 849.9413 10.62 PS(18:0/22:0) 
367 3.65 0.0403 DOWN 787.6689 8.45 SM(d18:1/22:0) 
371 3.59 0.0406 UP 929.7541 10.63 TG(18:0/14:0/16:1(9Z)) 
105 3.59 0.0068 DOWN 1020.9890 12.06 TG(20:2/22:0/22:0) 
297 3.51 0.0283 UP 883.7589 10.30 TG(17:2/19:0/20:4) 
209 3.51 0.0166 DOWN 809.5890 7.17 SM(d18:1/22:0) 
414 3.51 0.0494 DOWN 669.6381 11.39 PC(15:0/19:3(9Z,12Z,15Z)) 
243 3.49 0.0206 DOWN 814.6234 7.90 TG(16:1/16:1/18:0) 
258 3.47 0.0227 DOWN 810.5919 7.17 PA(22:1(11Z)/22:0) 
72 3.47 0.0033 UP 422.2726 4.24 
Ammonium 
diheptylnaphthalenesulphonate 
94 3.45 0.0057 DOWN 911.6528 9.94 TG(17:2/17:2/20:5) 
413 3.43 0.0490 DOWN 871.1178 10.35 PE(19:0/0:0) 
378 3.42 0.0423 DOWN 668.6349 11.39 CE(18:1/0:0) 
266 3.40 0.0235 UP 596.4731 8.06 TG(17:0/18:2/20:1) 
190 3.37 0.0140 DOWN 830.5667 7.17 
PC(20:5(5Z,8Z,11Z,14Z,17Z)/
15:0) 
332 3.37 0.0346 DOWN 813.6200 7.90 
N-(15Z-tetracosenoyl)-sphing-
4-enine-1-phosphocholine 
265 3.36 0.0234 UP 845.7438 10.28 TG(16:1/16:1/18:2) 
187 3.35 0.0137 DOWN 834.5917 7.13 PA(20:0/22:0) 
102 3.34 0.0064 UP 157.1017 9.98 2,2-Dimethyl-2H-indene 
405 3.27 0.0476 DOWN 940.7394 10.06 TG(20:0/20:0/22:0) 
 140 
 
159 3.26 0.0112 DOWN 893.8359 11.11 PC(18:1/22:6) 
156 3.24 0.0110 DOWN 870.5402 7.13 PC(18:3(6Z,9Z,12Z)/18:0) 
193 3.22 0.0144 DOWN 808.5856 7.17 PC(16:0/22:5) 
164 3.21 0.0115 DOWN 854.5668 7.13 PC(20:5(5Z,8Z,11Z,14Z,17Z) 
396 3.21 0.0465 UP 1098.9430 11.53 
TG(14:0/18:4(6Z,9Z,12Z,15Z)
/22:4(7Z,10Z,13Z,16Z)) 
306 3.21 0.0293 UP 1095.9870 12.18 TG(15:0/15:0/16:1(9Z)) 
141 3.19 0.0100 DOWN 645.5601 11.15 Cholesteryl palmitelaidate 
174 3.17 0.0123 DOWN 855.5701 7.13 
PC(16:0/22:5(4Z,7Z,10Z,13Z,
16Z)) 
280 3.17 0.0260 DOWN 772.5848 7.39 PE(20:2(5Z,8Z)/18:0) 
148 3.17 0.0104 DOWN 892.8322 11.11 
TG(16:1(9Z)/17:1(9Z)/17:2(9
Z,12Z)) 
368 3.16 0.0404 UP 1103.8950 11.34 TG(13:0/13:0/22:1(11Z)) 
279 3.14 0.0258 UP 1099.9470 11.55 TG(17:1/17:2/18:3) 
301 3.13 0.0285 UP 846.7465 10.28 TG(18:0/18:2/19:0) 
160 3.12 0.0113 DOWN 831.5703 7.17 PC(16:0/22:5) 
333 3.11 0.0347 DOWN 870.9271 10.35 PC(18:2/18:2) 
375 3.10 0.0416 DOWN 745.5579 7.40 PC(14:0/20:3(5Z,8Z,11Z)) 
269 3.09 0.0244 UP 918.8478 11.14 
TG(14:1(9Z)/18:2(9Z,12Z)/22:
5(7Z,10Z,13Z,16Z,19Z)) 
125 3.08 0.0087 UP 145.1016 9.98 2,2-Dimethyl-2H-indene 
155 3.07 0.0109 DOWN 646.5632 11.15 CE(16:1) 
321 3.07 0.0311 DOWN 667.6221 11.20 PE(18:2(9Z,12Z)/19:1(9Z)) 
178 3.04 0.0129 UP 847.5424 7.17 TG(18:0/14:0/16:1) 
251 3.04 0.0220 DOWN 811.6196 9.94 PA(O-16:0/14:0) 
246 3.04 0.0206 DOWN 832.7400 10.33 PC(20:1(11Z)/20:1(11Z)) 
61 3.03 0.0025 UP 928.7446 10.62 TG(16:1/20:5/22:6) 
93 3.02 0.0056 UP 927.7419 10.62 TG(18:3/20:2/20:2) 
89 3.00 0.0052 UP 443.2820 4.24 Diethylene glycol monooleate 
206 3.00 0.0163 UP 892.8246 10.95 TG(17:2/17:2/20:5) 
182 2.99 0.0133 DOWN 822.5409 7.19 PC(18:0/20:3) 
202 2.98 0.0158 UP 643.3635 9.44 Cholesteryl palmitelaidate 
298 2.97 0.0283 DOWN 727.5671 9.48 
Cholesteryl 11-hydroperoxy-
eicosatetraenoate 
60 2.97 0.0024 UP 563.4440 8.43 
1-tetradecanyl-2-(8-[3]-
ladderane-octanyl)-sn-glycerol 
134 2.96 0.0096 UP 1065.9210 11.27 
Tricyclo(4.4.2.0(1,6))dodeca-
2,4,7,9-tetraene 
129 2.95 0.0091 UP 564.4469 8.59 
1-tetradecyl-2-acetyl-sn-
glycero-3-phosphocholine 
257 2.93 0.0226 DOWN 852.5515 6.74 PC(20:4/22:6) 
290 2.90 0.0271 DOWN 858.7553 10.40 PC(16:0/18:3(6Z,9Z,12Z)) 
271 2.90 0.0248 UP 890.8183 10.95 
TG(13:0/18:4(6Z,9Z,12Z,15Z)
/20:1(11Z)) 
62 2.89 0.0026 UP 307.2614 9.98 
2,6-dimethyl-hexadecanoic 
acid 
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239 2.86 0.0204 UP 941.6986 10.46 
TG(12:0/21:0/22:3(10Z,13Z,1
6Z)) 
77 2.86 0.0038 UP 472.3115 5.04 octadecyldimethylsilanol 
347 2.84 0.0367 UP 916.8337 10.98 TG(17:0/19:1(9Z)/19:1(9Z)) 
275 2.83 0.0252 DOWN 534.2960 2.96 LPC(16:0/0:0) 
349 2.81 0.0372 DOWN 846.9242 10.45 PC(16:1/22:6) 
308 2.80 0.0297 UP 917.8362 10.98 TG(17:2/17:2/20:4) 
168 2.78 0.0119 DOWN 863.7896 10.75 PC(18:1/22:6) 
330 2.76 0.0340 DOWN 744.5540 6.76 PS(18:0/22:0) 
13 2.74 0.0001 UP 753.4884 6.52 DG(22:5/22:6/0:0) 
307 2.73 0.0296 DOWN 891.8212 10.95 TG(17:1/17:2/18:3) 
390 2.72 0.0455 DOWN 804.5543 6.55 PC(16:0/20:4) 
244 2.69 0.0206 DOWN 786.5917 7.21 SM(d18:1/24:1(15Z)) 
97 2.68 0.0061 UP 442.2793 4.24 
TG(12:0/15:1(9Z)/22:2(13Z,16
Z)) 
328 2.68 0.0335 DOWN 822.7554 10.58 
PE(18:1(11Z)/20:4(8Z,11Z,14
Z,17Z)) 
221 2.68 0.0175 DOWN 778.5362 6.59 
PC(16:0/20:4(5E,8E,11E,14E)
) 
18 2.67 0.0002 UP 725.4567 5.80 DG(20:5/22:6/0:0) 
203 2.65 0.0159 DOWN 627.4958 7.86 DG(17:1/20:5/0:0) 
133 2.64 0.0096 DOWN 895.6791 9.94 TG(17:2/17:2/20:5) 
310 2.63 0.0300 UP 945.7745 10.45 TG(14:0/20:2(11Z,14Z)/21:0) 
295 2.61 0.0280 UP 185.1333 9.98 Chamazulene 
397 2.60 0.0467 UP 859.7585 10.40 
TG(13:0/13:0/22:4(7Z,10Z,13
Z,16Z)) 
398 2.57 0.0468 DOWN 884.7706 10.45 PE(20:1(11Z)/16:1(9Z)) 
112 2.55 0.0072 DOWN 864.8022 10.91 TG(17:0/17:0/17:1) 
115 2.55 0.0075 UP 865.8049 10.91 TG(17:0/17:2/17:2) 
343 2.54 0.0359 DOWN 868.7407 10.19 PE(18:0/18:2) 
196 2.51 0.0148 UP 796.7309 10.33 TG(16:0/14:0/16:1) 
374 2.50 0.0416 UP 794.7241 10.33 TG(16:0/16:1/18:3) 
394 2.48 0.0463 DOWN 733.5575 6.88 DG(22:6/20:5) 
299 2.48 0.0284 DOWN 860.7709 10.57 TG(17:1/17:1/17:1) 
294 2.46 0.0280 UP 861.7738 10.57 TG(13:0/18:2(9Z,12Z)/22:0) 
341 2.44 0.0357 DOWN 795.7268 10.33 PE(21:0/20:3(8Z,11Z,14Z)) 
237 2.44 0.0197 UP 623.5004 8.56 TG(18:2/20:5/20:5) 
322 2.44 0.0322 UP 862.7772 10.57 TG(16:0/17:2/17:2) 
389 2.43 0.0451 UP 820.7401 10.40 TG(16:1/16:1/18:2) 
406 2.43 0.0480 DOWN 826.7767 10.76 
PC(17:1(9Z)/18:4(6Z,9Z,12Z,
15Z)) 
315 2.39 0.0304 DOWN 824.7614 10.58 PC(16:1/22:6) 
377 2.37 0.0419 UP 617.5866 11.40 
TG(13:0/18:2(9Z,12Z)/20:1(11
Z)) 
63 2.34 0.0028 UP 561.5246 10.99 
1-tetradecanyl-2-(8-[3]-
ladderane-octanyl)-sn-glycerol 
215 2.34 0.0170 UP 955.7716 10.78 TG(18:3/20:4/20:5) 
407 2.31 0.0482 DOWN 823.7584 10.58 PE(22:2/14:0) 
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325 2.30 0.0331 DOWN 750.5516 9.49 PC(17:2(9Z,12Z)/19:1(9Z)) 
404 2.29 0.0475 UP 596.4741 7.44 TG(17:0/17:0/17:1) 
352 2.28 0.0373 DOWN 658.6108 8.78 Cer(d18:1/23:0) 
230 2.28 0.0190 UP 891.7756 11.09 TG(16:1/17:1/18:1) 
340 2.27 0.0357 UP 862.7864 10.75 TG(16:0/18:1/19:0) 
403 2.27 0.0475 UP 935.8765 11.24 TG(18:3/18:3/20:1) 
410 2.27 0.0486 UP 595.4704 7.28 TG(18:3/18:3/18:3) 
344 2.25 0.0363 DOWN 749.5483 9.49 DG(21:0/22:6/0:0) 
108 2.22 0.0070 DOWN 991.9198 11.14 TG(18:3/20:2/20:2) 
393 2.21 0.0461 DOWN 864.6562 10.12 PC(20:2/20:5) 
355 2.21 0.0375 UP 444.2796 4.24 Diethylene glycol monooleate 
379 2.19 0.0425 DOWN 459.3295 1.22 
2,5-Bis(octyloxy)-4-
[(trimethylsilyl)ethynyl]benzal
dehyde 
384 2.19 0.0439 DOWN 837.6352 10.03 PA(22:1(11Z)/22:2(13Z,16Z)) 
391 2.19 0.0455 DOWN 768.7081 10.29 
TG(14:0/17:2(9Z,12Z)/22:3(10
Z,13Z,16Z)) 
188 2.18 0.0137 UP 918.7028 10.42 TG(18:2/18:3/18:3) 
386 2.16 0.0442 DOWN 371.3594 11.37 Neomethymycin 
416 2.16 0.0495 DOWN 769.7112 10.29 PE(20:2(5Z,8Z)/18:0) 
311 2.14 0.0301 UP 897.6947 10.11 TG(17:0/18:0/18:2) 
376 2.14 0.0417 DOWN 922.6975 10.09 TG(18:2/18:3/20:0) 
334 2.12 0.0347 UP 898.6977 10.12 TG(17:1/17:1/17:2) 
387 2.11 0.0447 DOWN 823.7488 10.39 PC(16:1/22:6) 
320 2.11 0.0308 DOWN 872.6811 10.05 SM (d18:1/12:0) 
189 2.11 0.0139 UP 921.8233 11.41 TG(17:2/18:1/18:3) 
382 2.09 0.0430 DOWN 257.2271 11.36 
1,4a-dimethyl-7-(propan-2-yl)-
1,2,3,4,4a,9,10,10a-
octahydrophenanthrene 
201 2.08 0.0153 DOWN 784.7234 10.93 PC(16:0/20:5) 
48 2.08 0.0017 UP 486.4159 5.74 
12-[Bis(2-
hydroxyethyl)amino]-12-
oxododecyl dodecanoate 
211 2.08 0.0170 UP 783.7199 10.93 TG(17:2/18:2/18:2) 
123 2.07 0.0084 DOWN 550.5931 10.43 PE(19:0/18:3(9Z,12Z,15Z)) 
336 2.02 0.0350 UP 575.5047 10.68 TG(17:1/17:2/20:5) 
329 2.02 0.0338 DOWN 588.4687 7.48 PC(16:1/22:6) 
54 28.8 0.002 DOWN 1102.055 12.308 NA 
65 26.5 0.003 DOWN 1139.065 12.293 NA 
55 23 0.002 DOWN 1101.052 12.301 NA 
58 18.7 0.002 DOWN 1100.041 12.16 NA 
59 16.8 0.002 DOWN 1140.07 12.293 NA 
2 15.7 2E-06 UP 1048.913 11.102 NA 
1 14.8 1E-06 UP 1047.91 11.098 NA 
83 14.4 0.005 DOWN 1099.037 12.16 NA 
184 12.4 0.013 UP 1123.015 12.644 NA 
179 12.1 0.013 UP 1124.018 12.647 NA 
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66 10.9 0.003 DOWN 1126.055 12.182 NA 
158 10.4 0.011 DOWN 1128.07 12.331 NA 
95 9.89 0.006 UP 1099.94 12.438 NA 
120 9.58 0.008 UP 1100.942 12.43 NA 
140 9.45 0.01 DOWN 1155.098 12.529 NA 
116 8.89 0.008 UP 1095.988 12.434 NA 
99 8.74 0.006 UP 1094.984 12.432 NA 
227 8.7 0.019 UP 1080.932 11.401 NA 
176 8.58 0.013 DOWN 1127.067 12.333 NA 
153 8.53 0.011 DOWN 1156.101 12.529 NA 
181 8.11 0.013 UP 1078.961 12.438 NA 
69 7.93 0.003 DOWN 1151.066 12.26 NA 
229 7.64 0.019 UP 1077.957 12.434 NA 
137 7.54 0.01 DOWN 1154.086 12.389 NA 
106 7.4 0.007 DOWN 1153.082 12.389 NA 
273 7.03 0.025 DOWN 680.634 11.329 NA 
12 6.68 1E-04 UP 471.0857 1.2465 NA 
121 6.67 0.008 UP 1081.972 12.331 NA 
50 6.64 0.002 UP 1122.003 12.464 NA 
96 6.58 0.006 UP 1096.991 12.432 NA 
44 6.47 0.001 UP 1120.999 12.468 NA 
27 6.43 5E-04 UP 1097.993 12.434 NA 
79 6.34 0.004 UP 1137.022 12.434 NA 
32 6.32 6E-04 UP 1195.123 11.721 NA 
46 6.19 0.001 UP 1139.032 12.434 NA 
10 6.08 7E-05 UP 1076.945 11.846 NA 
24 6.03 3E-04 UP 1196.125 11.721 NA 
98 5.99 0.006 UP 1082.976 12.335 NA 
162 5.86 0.011 UP 1071.907 12.226 NA 
114 5.83 0.007 DOWN 1182.116 12.59 NA 
64 5.53 0.003 UP 1067.142 12.234 NA 
17 5.49 2E-04 UP 1096.991 12.177 NA 
20 5.49 2E-04 UP 1138.027 12.43 NA 
124 5.46 0.009 DOWN 397.3832 11.61 NA 
175 5.3 0.012 DOWN 381.3523 11.321 NA 
70 5.13 0.003 UP 1136.011 12.427 NA 
250 4.99 0.022 UP 199.1488 9.2729 NA 
126 4.92 0.009 DOWN 370.3555 11.65 NA 
56 4.92 0.002 UP 1052.936 12.149 NA 
34 4.9 7E-04 UP 1118.984 12.312 NA 
52 4.9 0.002 UP 1053.941 12.147 NA 
33 4.89 6E-04 UP 1048.913 11.666 NA 
183 4.82 0.013 DOWN 383.3678 11.321 NA 
39 4.8 9E-04 UP 1119.987 12.309 NA 
195 4.75 0.015 DOWN 384.371 11.327 NA 
132 4.72 0.009 DOWN 1181.113 12.597 NA 
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21 4.71 2E-04 UP 1068.96 12.234 NA 
45 4.67 0.001 UP 1047.909 11.666 NA 
278 4.56 0.026 UP 213.1647 9.2663 NA 
37 4.52 8E-04 UP 1021.895 11.632 NA 
4 4.5 2E-05 UP 1079.964 11.985 NA 
9 4.48 6E-05 UP 1077.958 11.982 NA 
7 4.47 3E-05 UP 1078.961 11.982 NA 
23 4.45 2E-04 UP 1075.939 11.846 NA 
49 4.31 0.002 UP 1080.968 12.167 NA 
53 4.18 0.002 UP 1066.954 12.233 NA 
74 4.18 0.003 UP 1098.996 12.434 NA 
40 4.15 0.001 UP 1022.898 11.632 NA 
107 4.06 0.007 UP 178.1679 11.985 NA 
26 4.02 4E-04 UP 492.2923 5.0213 NA 
84 4 0.005 UP 1049.927 12.23 NA 
149 4 0.01 UP 1050.929 12.23 NA 
136 3.93 0.01 DOWN 1125.05 12.182 NA 
35 3.93 7E-04 UP 1118.98 12.147 NA 
14 3.83 1E-04 UP 1049.926 11.807 NA 
177 3.82 0.013 DOWN 1017.936 11.192 NA 
287 3.8 0.027 DOWN 1018.939 11.192 NA 
142 3.8 0.01 DOWN 1020.956 11.387 NA 
36 3.77 7E-04 UP 1066.954 12.069 NA 
90 3.73 0.005 UP 1091.956 12.123 NA 
71 3.72 0.003 UP 1090.953 12.121 NA 
167 3.71 0.012 UP 1069.892 11.658 NA 
192 3.69 0.014 UP 159.1172 9.2654 NA 
78 3.69 0.004 UP 1067.957 12.232 NA 
131 3.68 0.009 UP 143.0856 9.9803 NA 
169 3.66 0.012 DOWN 1021.959 11.387 NA 
42 3.64 0.001 UP 1092.966 12.114 NA 
200 3.62 0.015 UP 145.1015 9.2654 NA 
67 3.61 0.003 UP 1050.929 12.063 NA 
236 3.58 0.02 DOWN 688.6094 11.526 NA 
104 3.58 0.007 UP 1051.933 12.237 NA 
214 3.57 0.017 DOWN 1019.952 11.389 NA 
29 3.55 5E-04 UP 1107.98 12.232 NA 
276 3.48 0.025 UP 1126.972 11.693 NA 
122 3.46 0.008 UP 1116.962 12.154 NA 
381 3.43 0.043 DOWN 1130.012 11.299 NA 
22 3.37 2E-04 UP 1050.929 11.804 NA 
73 3.29 0.003 UP 1092.969 12.275 NA 
80 3.29 0.004 UP 1109.998 12.234 NA 
88 3.28 0.005 UP 158.107 9.9823 NA 
228 3.27 0.019 UP 1070.894 11.659 NA 
82 3.23 0.005 UP 1066.924 11.269 NA 
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163 3.21 0.011 UP 119.0857 9.9893 NA 
219 3.2 0.017 UP 595.4702 7.4417 NA 
51 3.14 0.002 UP 1051.933 11.807 NA 
165 3.07 0.012 UP 554.3315 5.9481 NA 
43 3.05 0.001 UP 1093.972 12.269 NA 
38 3.02 9E-04 UP 1051.933 12.059 NA 
101 2.99 0.006 UP 172.1222 9.9781 NA 
75 2.95 0.003 UP 1108.992 12.07 NA 
399 2.93 0.047 UP 1039.925 11.629 NA 
135 2.91 0.01 UP 1094.984 12.241 NA 
380 2.91 0.043 UP 596.4736 7.2838 NA 
362 2.9 0.039 UP 1140.978 11.529 NA 
57 2.89 0.002 UP 1049.926 12.056 NA 
348 2.87 0.037 UP 1108.992 12.233 NA 
171 2.81 0.012 UP 307.2041 8.5588 NA 
191 2.8 0.014 DOWN 687.6074 11.526 NA 
41 2.79 0.001 UP 1135.006 12.286 NA 
253 2.77 0.022 DOWN 618.619 8.7756 NA 
146 2.75 0.01 UP 471.3133 5.0384 NA 
316 2.74 0.031 DOWN 351.2273 4.464 NA 
241 2.74 0.021 UP 641.3656 9.4436 NA 
286 2.74 0.027 UP 536.8963 7.6779 NA 
170 2.67 0.012 UP 563.4438 8.5972 NA 
81 2.66 0.005 UP 1107.98 12.066 NA 
213 2.62 0.017 UP 159.1174 9.982 NA 
118 2.59 0.008 UP 464.261 4.2408 NA 
264 2.59 0.023 UP 171.1173 9.9832 NA 
144 2.53 0.01 UP 508.7142 7.0944 NA 
147 2.52 0.01 UP 1093.971 11.849 NA 
345 2.52 0.036 UP 417.0752 1.2502 NA 
289 2.51 0.027 UP 555.3347 5.9481 NA 
365 2.47 0.04 UP 213.1648 9.9821 NA 
335 2.46 0.035 DOWN 295.0924 1.391 NA 
360 2.45 0.038 UP 173.133 9.3987 NA 
317 2.43 0.031 DOWN 1112.035 12.093 NA 
245 2.42 0.021 UP 147.1173 9.9821 NA 
154 2.41 0.011 DOWN 550.6283 8.1677 NA 
277 2.41 0.025 DOWN 370.3561 11.391 NA 
260 2.4 0.023 UP 199.149 9.9848 NA 
288 2.4 0.027 DOWN 369.3527 11.389 NA 
103 2.37 0.007 UP 1097.923 11.849 NA 
128 2.36 0.009 UP 1071.907 12.068 NA 
358 2.36 0.038 DOWN 519.3255 2.9611 NA 
263 2.33 0.023 DOWN 149.0237 5.2268 NA 
208 2.31 0.016 DOWN 394.3014 5.0542 NA 
259 2.28 0.023 UP 576.3129 5.9481 NA 
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342 2.25 0.036 DOWN 129.0547 5.0571 NA 
31 2.23 5E-04 DOWN 116.9678 12.012 NA 
386 2.16 0.044 DOWN 371.3594 11.375 NA 
282 2.14 0.026 UP 173.1331 9.9931 NA 
351 2.14 0.037 UP 105.0699 9.5956 NA 
302 2.12 0.029 DOWN 393.298 5.0571 NA 
172 2.11 0.012 UP 536.7489 7.6779 NA 
356 2.11 0.038 UP 1109.998 12.066 NA 
224 2.09 0.018 UP 1098.924 11.845 NA 
261 2.08 0.023 UP 1072.91 12.072 NA 
262 2.08 0.023 DOWN     428.3056 1.22 NA 
337 2.01 0.035 UP 91.05358 9.5957 NA 
 
Table B.11. Summary of significant features of enriched lipid droplets from young and old mouse liver 
observed in positive electrospray ionization. NA: Not Assigned, PC: Phophatidylcholine, PE: 
Phophatidylethanolamine, SM: Sphingomyelin, CE: Cholesteryl ester, PA: Phophatidic acid, PS: 
Phophatidylserine, TG: Triglyceride, DG: Diacylglycerol. 
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ID Fold p-value Change m/z Rt Name 
2 93.96 0.0009 UP 983.4781 1.51 Lanatoside 
6 3.45 0.0089 DOWN 473.2378 5.95 PC(22:6/15:0) 
8 3.24 0.0139 DOWN 772.5848 6.39 PE(18:1/20:4) 
1 3.05 0.0005 UP 254.2486 4.24 Palmitamide 
9 2.54 0.014 DOWN 182.1185 1.39 
Ethyl 3-(piperidin-1-yl) prop-
2-enoate 
7 2.31 0.013 DOWN 764.523 7.01 PC(15:0/20:5) 
12 2.05 0.0417 UP 790.5383 7.38 PE(18:0/22:6) 
10 2 0.021 DOWN 605.4539 6.56 PA(16:0/14:1) 
3 3.29 0.0015 UP 553.319 5.95 NA 
4 3.23 0.0031 UP 245.0398 1.39 NA 
5 2.98 0.0059 UP 552.3158 1.79 NA 
11 2.06 0.0407 UP 791.5418 7.38 NA 
 
Table B.12. Summary of significant features of enriched lipid droplets from young and old mouse liver 
observed in negative electrospray ionization. 
